BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590. [PMID: 22607822 DOI: 10.1016/s0140-6736(12)60367-5] [Cited by in Crossref: 1459] [Cited by in F6Publishing: 599] [Article Influence: 145.9] [Reference Citation Analysis]
Number Citing Articles
1 Weldegiorgis M, Woodward M. Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom. BMC Nephrol 2022;23. [DOI: 10.1186/s12882-022-02932-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Hsu L, Teng M, Wu S, Chou H, Ko Y. Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study. IJMS 2022;23:10418. [DOI: 10.3390/ijms231810418] [Reference Citation Analysis]
3 Wang J, Sun Q, An Y, Liu J, Leng S, Wang G. The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension. Front Endocrinol 2022;13:951635. [DOI: 10.3389/fendo.2022.951635] [Reference Citation Analysis]
4 Sykes AV, Patel N, Lee D, Taub PR. Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment. Curr Cardiol Rep 2022. [PMID: 36001215 DOI: 10.1007/s11886-022-01775-5] [Reference Citation Analysis]
5 Orringer CE, Grant JK, Tokgozoglu L. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms. Curr Atheroscler Rep 2022. [PMID: 36001213 DOI: 10.1007/s11883-022-01059-x] [Reference Citation Analysis]
6 Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik M. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2022;328:754-71. [PMID: 35997724 DOI: 10.1001/jama.2022.12138] [Reference Citation Analysis]
7 Navar AM, Peterson ED. Statin Recommendations for Primary Prevention: More of the Same or Time for a Change? JAMA 2022;328:716-8. [PMID: 35997751 DOI: 10.1001/jama.2022.12982] [Reference Citation Analysis]
8 Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr, Waring AA, Wilkins JT; Writing Committee. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2022:S0735-1097(22)05594-2. [PMID: 36031461 DOI: 10.1016/j.jacc.2022.07.006] [Reference Citation Analysis]
9 Belur AD, Shah AJ, Virani SS, Vorla M, Kalra DK. Role of Lipid-Lowering Therapy in Peripheral Artery Disease. J Clin Med 2022;11:4872. [PMID: 36013107 DOI: 10.3390/jcm11164872] [Reference Citation Analysis]
10 Osadnik T, Goławski M, Lewandowski P, Morze J, Osadnik K, Pawlas N, Lejawa M, Jakubiak GK, Mazur A, Schwingschackl L, Gąsior M, Banach M. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res 2022;183:106402. [PMID: 35988871 DOI: 10.1016/j.phrs.2022.106402] [Reference Citation Analysis]
11 Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther 2022;7:265. [PMID: 35918332 DOI: 10.1038/s41392-022-01125-5] [Reference Citation Analysis]
12 Rong S, Li B, Chen L, Sun Y, Du Y, Liu B, Robinson JG, Bao W. Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population. J Am Heart Assoc 2022;:e023690. [PMID: 35904192 DOI: 10.1161/JAHA.121.023690] [Reference Citation Analysis]
13 Blazing M, Braunwald E, de Lemos J, Murphy S, Pedersen T, Pfeffer M, White H, Wiviott S, Clearfield M, Downs JR, Gotto, Jr A, Weis S, Fellström B, Holdaas H, Jardine A, Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield J, Rahman M, Simpson L, Koren M, Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H, Knopp (deceased) R, Cobbe S, Schmieder R, Zannad F, Betteridge DJ, Colhoun H, Durrington P, Fuller (deceased) J, Hitman GA, Neil A, Hawkins CM, Moyé L, Sacks F, Kjekshus J, Wikstrand J, Wanner C, Krane V, Franzosi MG, Latini R, Lucci D, Maggioni A, Marchioli R, Nicolis E, Tavazzi L, Tognoni G, Bosch J, Lonn E, Yusuf S, Armitage J, Bowman L, Collins R, Keech A, Landray M, Parish S, Peto R, Sleight P, Kastelein J, Glynn R, Koenig W, Macfadyen J, Ridker P, Macmahon S, Marschner I, Tonkin A, Shaw J, Simes J, Serruys P, Knatterud (deceased) G, Ford I, Macfarlane P, Packard C, Sattar N, Shepherd J, Trompet S, Cannon CP, Amarenco P, Welch KM, Wilhelmsen L, Barter P, Larosa J, Kean S, Robertson M, Young R, Arashi H, Clarke R, Flather M, Goto S, Goldbourt U, Hopewell J, Hovingh K, Kitas G, Newman C, Sabatine MS, Schwartz G, Smeeth L, Tobert J, Varigos J, Yamaguchi J, Kearney P, Jukema JW, Byington R. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)01545-8] [Reference Citation Analysis]
14 Zhao X, Liu C, Zhou P, Sheng Z, Li J, Zhou J, Chen R, Wang Y, Chen Y, Song L, Zhao H, Yan H. Development and Validation of a Prediction Rule for Major Adverse Cardiac and Cerebrovascular Events in High-Risk Myocardial Infarction Patients After Primary Percutaneous Coronary Intervention. Clin Interv Aging 2022;17:1099-111. [PMID: 35880211 DOI: 10.2147/CIA.S358761] [Reference Citation Analysis]
15 Citarella A, Cammarota S, Bernardi FF, Caliendo L, D'Andrea A, Fimiani B, Fogliasecca M, Pacella D, Pagnotta R, Trama U, Zito GB, Cillo M, Vercellone A. Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy. J Clin Med 2022;11:4344. [PMID: 35893434 DOI: 10.3390/jcm11154344] [Reference Citation Analysis]
16 Pirillo A, Catapano AL. Inclisiran: How Widely and When Should We Use It? Curr Atheroscler Rep 2022. [PMID: 35877035 DOI: 10.1007/s11883-022-01056-0] [Reference Citation Analysis]
17 Matthias AT, Kaushalya J, Somathilake G, Garusinghe C. Utilization of statins in patients with type 2 diabetes mellitus: the practice in a lower middle income South Asian country. Int J Diabetes Dev Ctries. [DOI: 10.1007/s13410-022-01107-x] [Reference Citation Analysis]
18 Pasha R, Azmi S, Ferdousi M, Kalteniece A, Bashir B, Gouni-Berthold I, Malik RA, Soran H. Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review. Clin Ther 2022:S0149-2918(22)00138-2. [PMID: 35810030 DOI: 10.1016/j.clinthera.2022.03.013] [Reference Citation Analysis]
19 Offiah G, O'Connor C, Kennedy C, Gallagher J, O'Connor P, McAdam B, Ray KK, Schoonen M, Maher V. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals? Ir J Med Sci 2022. [PMID: 35776266 DOI: 10.1007/s11845-022-03050-6] [Reference Citation Analysis]
20 Durai V, Redberg RF. Statin therapy for the primary prevention of cardiovascular disease: Cons. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.07.003] [Reference Citation Analysis]
21 Goldsborough E, Osuji N, Blaha MJ. Assessment of Cardiovascular Disease Risk. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.02.005] [Reference Citation Analysis]
22 Li B, Wang J, Zhou X, Liu Y, Wang W, Gao Z, Tang X, Yan L, Wan Q, Luo Z, Qin G, Chen L, Ning G, Mu Y. Chinese Visceral Adiposity Index Is More Closely Associated With Hypertension and Prehypertension Than Traditional Adiposity Indices in Chinese Population: Results From the REACTION Study. Front Endocrinol 2022;13:921997. [DOI: 10.3389/fendo.2022.921997] [Reference Citation Analysis]
23 Li L, Ouyang F, He J, Qiu D, Luo D, Xiao S. Associations of Socioeconomic Status and Healthy Lifestyle With Incidence of Dyslipidemia: A Prospective Chinese Governmental Employee Cohort Study. Front Public Health 2022;10:878126. [PMID: 35757615 DOI: 10.3389/fpubh.2022.878126] [Reference Citation Analysis]
24 Boettiger DC, Chattranukulchai P. Considering Whether Countries Participating in Clinical Trials can Afford the Intervention. Health Policy Plan 2022:czac044. [PMID: 35674252 DOI: 10.1093/heapol/czac044] [Reference Citation Analysis]
25 Smetana GW, Benson MD, Juraschek SP, Burns RB. Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 2022;175:862-72. [PMID: 35696686 DOI: 10.7326/M22-0908] [Reference Citation Analysis]
26 Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, Schwendeman EJ, Mohammad SJ, Diallo M, Revan R, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. Heart Failure Clinics 2022. [DOI: 10.1016/j.hfc.2022.02.003] [Reference Citation Analysis]
27 Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.05.069] [Reference Citation Analysis]
28 Xiao W, Li J, Huang X, Zhu Q, Liu T, Xie H, Deng Z, Tang Y. Mediation roles of neutrophils and high-density lipoprotein (HDL) on the relationship between HLA-DQB1 and rosacea. Ann Med 2022;54:1530-7. [PMID: 35622385 DOI: 10.1080/07853890.2022.2077427] [Reference Citation Analysis]
29 Khan Minhas AM, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, Greene SJ, Fudim M, Warraich HJ, Shapiro MD, Al-Kindi SG, Sperling L, Virani SS. National Trends and Disparities in Statin Use for Ischemic Heart Disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. Am Heart J 2022:S0002-8703(22)00109-0. [PMID: 35644222 DOI: 10.1016/j.ahj.2022.05.015] [Reference Citation Analysis]
30 Desai NR, Campbell C, Electricwala B, Petrou M, Trueman D, Woodcock F, Cristino J. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. Am J Cardiovasc Drugs 2022. [PMID: 35595929 DOI: 10.1007/s40256-022-00534-9] [Reference Citation Analysis]
31 Wang J, Wang Y, Li Y, Hu Y, Jin L, Wang W, Gao Z, Tang X, Yan L, Wan Q, Luo Z, Qin G, Chen L, Gu W, Lyv Z, Mu Y. High Normal Urinary Albumin–Creatinine Ratio Is Associated With Hypertension, Type 2 Diabetes Mellitus, HTN With T2DM, Dyslipidemia, and Cardiovascular Diseases in the Chinese Population: A Report From the REACTION Study. Front Endocrinol 2022;13:864562. [DOI: 10.3389/fendo.2022.864562] [Reference Citation Analysis]
32 Madison CJ, Heinrich MC, Thompson RF, Yu WY. Statin use is associated with improved overall survival in patients with melanoma. Melanoma Res 2022. [PMID: 35579692 DOI: 10.1097/CMR.0000000000000822] [Reference Citation Analysis]
33 Kim JH, Cha J, Lim S, An J, Kim M, Hong SJ, Joo HJ, Park JH, Yu CW, Lim D, Byeon K, Kim S, Shin E, Cha KS, Chae JK, Ahn Y, Jeong MH, Ahn TH. Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study. JCM 2022;11:2650. [DOI: 10.3390/jcm11092650] [Reference Citation Analysis]
34 Arora A, Tripodi GL, Kareinen I, Berg M, Forteza MJ, Gisterå A, Griepke S, Casagrande FB, Martins JO, Abdalla DSP, Cole J, Monaco C, Ketelhuth DFJ. Genetic Deficiency of Indoleamine 2,3-dioxygenase Aggravates Vascular but Not Liver Disease in a Nonalcoholic Steatohepatitis and Atherosclerosis Comorbidity Model. IJMS 2022;23:5203. [DOI: 10.3390/ijms23095203] [Reference Citation Analysis]
35 Schiele F, Pérez de Isla L, Arca M, Vlachopoulos C. Is it Time for Single-Pill Combinations in Dyslipidemia? Am J Cardiovasc Drugs 2022;22:239-49. [PMID: 34549371 DOI: 10.1007/s40256-021-00498-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Bots SH, Onland-Moret NC, Jancev M, Hollander M, Tulevski II, Hofstra L, Somsen GA, den Ruijter HM. Statins are associated with a large reduction in all-cause mortality in women from a cardiac outpatient population. Open Heart 2022;9:e001900. [PMID: 35444049 DOI: 10.1136/openhrt-2021-001900] [Reference Citation Analysis]
37 Burger AL, Pogran E, Muthspiel M, Kaufmann CC, Jäger B, Huber K. New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. Biomedicines 2022;10:970. [DOI: 10.3390/biomedicines10050970] [Reference Citation Analysis]
38 Drapkina OM, Kontsevaya AV, Kalinina AM, Avdeev SM, Agaltsov MV, Alexandrova LM, Antsiferova AA, Aronov DM, Akhmedzhanov NM, Balanova YA, Balakhonova TV, Berns SA, Bochkarev MV, Bochkareva EV, Bubnova MV, Budnevsky AV, Gambaryan MG, Gorbunov VM, Gorny BE, Gorshkov AY, Gumanova NG, Dadaeva VA, Drozdova LY, Egorov VA, Eliashevich SO, Ershova AI, Ivanova ES, Imaeva AE, Ipatov PV, Kaprin AD, Karamnova NS, Kobalava ZD, Konradi AO, Kopylova OV, Korostovtseva LS, Kotova MB, Kulikova MS, Lavrenova EA, Lischenko OV, Lopatina MV, Lukina YV, Lukyanov MM, Mayev IV, Mamedov MN, Markelova SV, Martsevich SY, Metelskaya VA, Meshkov AN, Milushkina OY, Mukaneeva DK, Myrzamatova AO, Nebieridze DV, Orlov DO, Poddubskaya EA, Popovich MV, Popovkina OE, Potievskaya VI, Prozorova GG, Rakovskaya YS, Rotar OP, Rybakov IA, Sviryaev YV, Skripnikova IA, Skoblina NA, Smirnova MI, Starinsky VV, Tolpygina SN, Usova EV, Khailova ZV, Shalnova SA, Shepel RN, Shishkova VN, Yavelov IS. 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovasc Ther Prev 2022;21:3235. [DOI: 10.15829/1728-8800-2022-3235] [Reference Citation Analysis]
39 Chaure-pardos A, Aguilar-palacio I, Rabanaque MJ, Lallana MJ, Maldonado L, Castel-feced S, Librero J, Casasnovas JA, Malo S. Effectiveness of Statins for Primary Prevention of Cardiovascular Disease in Low- and Medium-Risk Males: A Causal Inference Approach with Observational Data. JPM 2022;12:658. [DOI: 10.3390/jpm12050658] [Reference Citation Analysis]
40 Liu M, Cao Y, Hu Y, Zhang Z, Ji S, Shi L, Tao G. MiR-199a-3p Restrains Foaming and Inflammation by Regulating RUNX1 in Macrophages. Mol Biotechnol. [DOI: 10.1007/s12033-022-00484-2] [Reference Citation Analysis]
41 Amadi PU, Agomuo EN, Amadi JA, Bob-chile Agada AI, Njoku UC, Ogunwa CS, Odika PC, Osuoha JO, Ogbolosingha AJ, Adumekwe CW, Chigbu IN. Efficacy of using walnuts as statin adjuvants in hypertension management. Clinical and Experimental Hypertension. [DOI: 10.1080/10641963.2022.2065287] [Reference Citation Analysis]
42 Marchini T, Malchow S, Caceres L, El Rabih AAH, Hansen S, Mwinyella T, Spiga L, Piepenburg S, Horstmann H, Olawale T, Li X, Mitre LS, Gissler MC, Bugger H, Zirlik A, Heidt T, Hilgendorf I, Stachon P, von zur Muehlen C, Bode C, Wolf D. Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease. Front Cardiovasc Med 2022;9:826729. [DOI: 10.3389/fcvm.2022.826729] [Reference Citation Analysis]
43 L.j. Visseren F, Mach F, M. Smulders Y, Carballo D, C. Koskinas K, Bäck M, Benetos A, Biffi A, Manuel Boavida J, Capodanno D, Cosyns B, Crawford C, H. Davos C, Desormais I, Di Angelantonio E, H. Franco O, Halvorsen S, Richard Hobbs F, Hollander M, A. Jankowska E, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, P. Tsioufis K, van Dis I, C. van Gelder I, Wanner C, Williams B. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.10.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Rao SJ, Martin SS, Lawson SM, Hailu T, Davis DM, Nasir K, Cainzos-achirica M, Blumenthal RS, Sharma G. Evaluating the Role of Statins in Prevention of Preeclampsia: Deeper Insights into Maternal Cardiometabolic Changes. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.04.007] [Reference Citation Analysis]
45 Takahashi D, Wada H, Ogita M, Yasuda K, Nishio R, Takeuchi M, Shitara J, Tsuboi S, Dohi T, Suwa S, Miyauchi K, Daida H, Minamino T. Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. Am J Cardiol 2022;168:11-6. [PMID: 35067346 DOI: 10.1016/j.amjcard.2021.12.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Canan A, Navar AM. Limitations of Observational Studies for Aspirin in Primary Prevention and the Need for Randomized Trials. Radiol Cardiothorac Imaging 2022;4:e220079. [PMID: 35506143 DOI: 10.1148/ryct.220079] [Reference Citation Analysis]
47 Forteza MJ, Ketelhuth DFJ. Metabolism in atherosclerotic plaques: immunoregulatory mechanisms in the arterial wall. Clin Sci (Lond) 2022;136:435-54. [PMID: 35348183 DOI: 10.1042/CS20201293] [Reference Citation Analysis]
48 Brassington K, Selemidis S, Bozinovski S, Vlahos R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin Sci (Lond) 2022;136:405-23. [PMID: 35319068 DOI: 10.1042/CS20210835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sut S, Tahmasebi A, Ferri N, Ferrarese I, Rossi I, Panighel G, Lupo MG, Maggi F, Karami A, Dall'Acqua S. NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9. Molecules 2022;27:2256. [PMID: 35408655 DOI: 10.3390/molecules27072256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Trane RM, Kang H. Nonparametric bounds in two-sample summary-data Mendelian randomization: Some cautionary tales for practice. Stat Med 2022. [PMID: 35355302 DOI: 10.1002/sim.9368] [Reference Citation Analysis]
51 Hassen LJ, Scarfone SR, Milks MW. Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. Geriatrics 2022;7:38. [DOI: 10.3390/geriatrics7020038] [Reference Citation Analysis]
52 Xu C, Li H, Tang CK. Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications. Metabolism 2022;:155180. [PMID: 35311663 DOI: 10.1016/j.metabol.2022.155180] [Reference Citation Analysis]
53 Schillemans T, Donat-Vargas C, Lindh CH, de Faire U, Wolk A, Leander K, Åkesson A. Per- and Polyfluoroalkyl Substances and Risk of Myocardial Infarction and Stroke: A Nested Case-Control Study in Sweden. Environ Health Perspect 2022;130:37007. [PMID: 35285690 DOI: 10.1289/EHP9791] [Reference Citation Analysis]
54 Byrne P, Demasi M, Jones M, Smith SM, O'Brien KK, DuBroff R. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med 2022. [PMID: 35285850 DOI: 10.1001/jamainternmed.2022.0134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
55 Liao J, Yang L, Zhou L, Zhao H, Qi X, Cui Y, Ouyang D. The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. Front Pharmacol 2022;13:755469. [DOI: 10.3389/fphar.2022.755469] [Reference Citation Analysis]
56 Bideberi AT, Mutagaywa R. Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania. Diabetes Metab Syndr Obes 2022;15:633-46. [PMID: 35250285 DOI: 10.2147/DMSO.S347765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Kurmanbekova BT, Noruizbaeva AM. Cardiovascular Effects of Metformin. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;18:97-102. [DOI: 10.20996/1819-6446-2022-02-12] [Reference Citation Analysis]
58 Lehoux D, Far AR, Kallend D, Wijngaard PL, Zerler B. Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.115978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Jiang Z, Qu H, Lin G, Shi D, Chen K, Gao Z. Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Nutr 2022;9:812294. [DOI: 10.3389/fnut.2022.812294] [Reference Citation Analysis]
60 Gu J, Sanchez R, Chauhan A, Fazio S, Wong N. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update. American Journal of Preventive Cardiology 2022. [DOI: 10.1016/j.ajpc.2022.100336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Stone NJ, Smith SC Jr, Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M, Pencina MJ, Grundy SM. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:819-36. [PMID: 35210038 DOI: 10.1016/j.jacc.2021.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
62 Raal FJ, Mohamed F. Statins: are they appropriate for all patients? The Lancet Global Health 2022;10:e305-6. [DOI: 10.1016/s2214-109x(21)00572-6] [Reference Citation Analysis]
63 Headen AC, Siaw-asamoah A, Julien HM. Race and Modifiable Factors Influencing Cardiovascular Disease. Medical Clinics of North America 2022;106:401-9. [DOI: 10.1016/j.mcna.2021.11.008] [Reference Citation Analysis]
64 Camacho X, Nedkoff L, Wright FL, Nghiem N, Buajitti E, Goldacre R, Rosella LC, Seminog O, Tan EJ, Hayes A, Hayen A, Wilson N, Blakely T, Clarke P. Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1·95 million events in 80·4 million people in four countries. The Lancet Public Health 2022;7:e229-39. [DOI: 10.1016/s2468-2667(22)00006-8] [Reference Citation Analysis]
65 Abiri P, Luo Y, Huang Z, Cui Q, Duarte-vogel S, Roustaei M, Chang C, Xiao X, Packard R, Cavallero S, Ebrahimi R, Benharash P, Chen J, Tai Y, Hsiai TK. 3-Dimensional electrical impedance spectroscopy for in situ endoluminal mapping of metabolically active plaques. Sensors and Actuators B: Chemical 2022;354:131152. [DOI: 10.1016/j.snb.2021.131152] [Reference Citation Analysis]
66 Puri R, Mehta V, Duell P, Iyengar S, Yusuf J, Dalal J, Narasingan S, Kalra D, Kapoor A, Pradhan A, Mukhopadhyay S, Vijayaraghavan K, Aggarwal R, Muruganathan A, Prabhakar D, Misra S, Shetty S, Kasliwal RR, Bansal M, Khanna NN, Khan A, Melinkeri RP, Kumar S, Chakraborty RN, Bardoloi N, Sahoo P, Vinayagam P, Modi R, Nanda R, Wong ND. Evidence for Intensive LDL-C Lowering for Acute Coronary Syndrome: Recommendations from the Lipid Association of India. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.03.008] [Reference Citation Analysis]
67 Poznyak AV, Bezsonov EE, Borisov EE, Grechko AV, Kartuesov AG, Orekhov AN. Atherosclerosis in HIV Patients: What Do We Know so Far? Int J Mol Sci 2022;23:2504. [PMID: 35269645 DOI: 10.3390/ijms23052504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovasc Diabetol 2022;21:28. [PMID: 35193571 DOI: 10.1186/s12933-022-01466-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhang Y, Zhao X, Ding X, Chen H, Li H, Li W. Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8 mmol/L. Angiology 2022;:33197221075861. [PMID: 35191328 DOI: 10.1177/00033197221075861] [Reference Citation Analysis]
70 Lin Y, Yang Q, Liu Z, Su B, Xu F, Li Y, Kang J, Zhou Z. Relationship between Apolipoprotein E Genotype and Lipoprotein Profile in Patients with Coronary Heart Disease. Molecules 2022;27:1377. [DOI: 10.3390/molecules27041377] [Reference Citation Analysis]
71 Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol 2022;226:S1171-81. [PMID: 32818477 DOI: 10.1016/j.ajog.2020.08.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
72 Ain Q, Nawab M, Ahmed T, Kazmi MH, Naikodi MAR. Evaluating the safety and efficacy of a polyherbal Unani formulation in dyslipidaemia-a prospective randomized controlled trial. J Ethnopharmacol 2022;:115036. [PMID: 35114340 DOI: 10.1016/j.jep.2022.115036] [Reference Citation Analysis]
73 Rao S, Jamal T, Khan MS, Michos E, Navar AM, Wang TJ, Greene S, Prabhakaran D, Khera A, Pandey A. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis 2022:S0033-0620(22)00005-6. [PMID: 35114251 DOI: 10.1016/j.pcad.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tsai M, Chen M, Huang Y, Liou H, Fang Y. The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study. Front Pharmacol 2022;12:804000. [DOI: 10.3389/fphar.2021.804000] [Reference Citation Analysis]
75 Mayo NL, Russell HA, Holt K, Williams GC. Implementation of a self-determination based clinical program to reduce cardiovascular disease risk. J Health Psychol 2022;:13591053211068124. [PMID: 35086378 DOI: 10.1177/13591053211068124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Mcnavish DE, German CA, Shapiro MD. Should a Statin be Given to All Hypertensive Patients? Curr Hypertens Rep. [DOI: 10.1007/s11906-022-01167-8] [Reference Citation Analysis]
77 Koh N, Ference BA, Nicholls SJ, Navar AM, Chew DP, Kostner K, He B, Tse HF, Dalal J, Santoso A, Ako J, Tada H, Park JJ, Ong ML, Lim E, Subramaniam T, Li YH, Phrommintikul A, Iyengar SS, Ray S, Park KW, Tan HC, Chunhamaneewat N, Yeo KK, Tan JWC. Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. Eur Cardiol 2021;16:e54. [PMID: 35024056 DOI: 10.15420/ecr.2021.36] [Reference Citation Analysis]
78 Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022:ehab892. [PMID: 35016208 DOI: 10.1093/eurheartj/ehab892] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 30.0] [Reference Citation Analysis]
79 Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;79:66-82. [PMID: 34991791 DOI: 10.1016/j.jacc.2021.10.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
80 van der Laarse A, Cobbaert CM. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine. Expert Rev Cardiovasc Ther 2022;:1-12. [PMID: 34937476 DOI: 10.1080/14779072.2021.2022475] [Reference Citation Analysis]
81 Giannini J, Padilla J, Eaton RP, Gonzales K, Schade DS. Prevention of Coronary Heart Disease: A Translational Clinical Challenge. WJCD 2022;12:11-23. [DOI: 10.4236/wjcd.2022.121002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S144-74. [PMID: 34964815 DOI: 10.2337/dc22-S010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 30.0] [Reference Citation Analysis]
83 Palacio-portilla E, Roquer J, Amaro S, Arenillas J, Ayo-martín O, Castellanos M, Freijo M, Fuentes B, García-pastor A, Gomis M, Gómez-choco M, López-cancio E, Martínez-sánchez P, Morales A, Rodríguez-yáñez M, Segura T, Serena J, Vivancos-mora J, de Leciñana M. Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. Neurología (English Edition) 2022;37:61-72. [DOI: 10.1016/j.nrleng.2020.07.021] [Reference Citation Analysis]
84 Nissen SE. Reply: The Fallacy of OTC Statin Therapy. J Am Coll Cardiol 2021;78:e327. [PMID: 34915993 DOI: 10.1016/j.jacc.2021.10.024] [Reference Citation Analysis]
85 Cobos-Palacios L, Sanz-Cánovas J, Muñoz-Ubeda M, Lopez-Carmona MD, Perez-Belmonte LM, Lopez-Sampalo A, Gomez-Huelgas R, Bernal-Lopez MR. Statin Therapy in Very Old Patients: Lights and Shadows. Front Cardiovasc Med 2021;8:779044. [PMID: 34912868 DOI: 10.3389/fcvm.2021.779044] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
86 Machlik ML, Hopstock LA, Wilsgaard T, Hansson P. Associations Between Intake of Fermented Dairy Products and Blood Lipid Concentrations Are Affected by Fat Content and Dairy Matrix - The Tromsø Study: Tromsø7. Front Nutr 2021;8:773468. [PMID: 34881281 DOI: 10.3389/fnut.2021.773468] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
87 Mortensen MB, Nordestgaard BG. Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. Atherosclerosis 2021;341:20-6. [PMID: 34959205 DOI: 10.1016/j.atherosclerosis.2021.12.002] [Reference Citation Analysis]
88 Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL, Casula M. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol 2021:zwab208. [PMID: 34871380 DOI: 10.1093/eurjpc/zwab208] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
89 Weng SF, Akyea RK, Man KK, Lau WCY, Iyen B, Blais JE, Chan EW, Siu CW, Qureshi N, Wong ICK, Kai J. Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS One 2021;16:e0260839. [PMID: 34855879 DOI: 10.1371/journal.pone.0260839] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Al Sayed N, Almahmeed W, Alnouri F, Al Waili K, Sabbour H, Sulaiman K, Zubaid M, Ray KK, Al-rasadi K. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East – 2021 update. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.11.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
91 Bai Z, Xu M, Mei Y, Hu T, Zhang P, Chen M, Lv W, Lu C, Tan S. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines 2021;9:1783. [PMID: 34944600 DOI: 10.3390/biomedicines9121783] [Reference Citation Analysis]
92 Bots SH, Inia JA, Peters SAE. Medication Adherence After Acute Coronary Syndrome in Women Compared With Men: A Systematic Review and Meta-Analysis. Front Glob Womens Health 2021;2:637398. [PMID: 34816194 DOI: 10.3389/fgwh.2021.637398] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
93 Grabarek BO, Boroń D, Morawiec E, Michalski P, Palazzo-Michalska V, Pach Ł, Dziuk B, Świder M, Zmarzły N. Crosstalk between Statins and Cancer Prevention and Therapy: An Update. Pharmaceuticals (Basel) 2021;14:1220. [PMID: 34959621 DOI: 10.3390/ph14121220] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
94 Chen X, Furukawa N, Jin DY, Liu Y, Stafford DW, Williams CM, Suhara Y, Tie JK. Naturally occurring UBIAD1 mutations differentially affect menaquinone biosynthesis and vitamin K-dependent carboxylation. FEBS J 2021. [PMID: 34813684 DOI: 10.1111/febs.16291] [Reference Citation Analysis]
95 Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol 2021. [PMID: 34811547 DOI: 10.1038/s41569-021-00638-w] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
96 Cimminiello C, Vlachopulos C, De Carlo M. The 2021 ESC guidelines on cardiovascular prevention: Whether the ends justify the means. Eur J Intern Med 2021:S0953-6205(21)00386-1. [PMID: 34823967 DOI: 10.1016/j.ejim.2021.11.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Dadon Z, Moriel M, Iakobishvili Z, Asher E, Samuel TY, Gavish D, Glikson M, Gottlieb S. Association of Contemporary Statin Pretreatment Intensity and LDL-C Levels on the Incidence of STEMI Presentation. Life (Basel) 2021;11:1268. [PMID: 34833144 DOI: 10.3390/life11111268] [Reference Citation Analysis]
98 Kohli-Lynch CN, Bellows BK, Zhang Y, Spring B, Kazi DS, Pletcher MJ, Vittinghoff E, Allen NB, Moran AE. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. J Am Coll Cardiol 2021;78:1954-64. [PMID: 34763772 DOI: 10.1016/j.jacc.2021.08.065] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Tippetts TS, Holland WL, Summers SA. Cholesterol - the devil you know; ceramide - the devil you don't. Trends Pharmacol Sci 2021;42:1082-95. [PMID: 34750017 DOI: 10.1016/j.tips.2021.10.001] [Reference Citation Analysis]
100 Dephillips C, Parikh PB, Stevens GA. Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use. The Journal for Nurse Practitioners 2021;17:1167-73. [DOI: 10.1016/j.nurpra.2021.08.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Borghi C, Levy BI. Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases 2021. [DOI: 10.1016/j.numecd.2021.11.015] [Reference Citation Analysis]
102 Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, Saraiva JFK, Chacra APM, Martinez TLR, Bahia LR, Fonseca FAH, Faludi AA, Sposito AC, Chagas ACP, Jannes CE, Amaral CK, Araújo DB, Cintra DE, Coutinho EDR, Cesena F, Xavier HT, Mota ICP, Giuliano ICB, Faria Neto JR, Kato JT, Bertolami MC, Miname MH, Castelo MHCG, Lavrador MSF, Machado RM, Souza PG, Alves RJ, Machado VA, Salgado Filho W. Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. Arq Bras Cardiol 2021;117:782-844. [PMID: 34709306 DOI: 10.36660/abc.20210788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. J Clin Lipidol 2021;15:782-8. [PMID: 34688585 DOI: 10.1016/j.jacl.2021.09.052] [Reference Citation Analysis]
104 Wolf AM. Rodent diet aids and the fallacy of caloric restriction. Mech Ageing Dev 2021;200:111584. [PMID: 34673082 DOI: 10.1016/j.mad.2021.111584] [Reference Citation Analysis]
105 Gordillo-Marañón M, Zwierzyna M, Charoen P, Drenos F, Chopade S, Shah T, Engmann J, Chaturvedi N, Papacosta O, Wannamethee G, Wong A, Sofat R, Kivimaki M, Price JF, Hughes AD, Gaunt TR, Lawlor DA, Gaulton A, Hingorani AD, Schmidt AF, Finan C. Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nat Commun 2021;12:6120. [PMID: 34675202 DOI: 10.1038/s41467-021-25731-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Melhem AL, Chourasia MK, Bigossi M, Maroteau C, Taylor A, Pola R, Dawed AY, Tornio A, Palmer CNA, Siddiqui MK. Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Front Genet 2021;12:713181. [PMID: 34659336 DOI: 10.3389/fgene.2021.713181] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Tejera CH, Minnier J, Fazio S, Safford MM, Colantonio LD, Irvin MR, Howard V, Zakai NA, Pamir N. High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults. Am J Prev Cardiol 2021;7:100198. [PMID: 34611638 DOI: 10.1016/j.ajpc.2021.100198] [Reference Citation Analysis]
108 Ballarano CA, Frishman WH. Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins. Cardiol Rev 2021;29:323-7. [PMID: 34609986 DOI: 10.1097/CRD.0000000000000383] [Reference Citation Analysis]
109 Imai M, Kawamura M, Kochi I, Matsuoka T, Kihara S, Yamamoto H. Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque. J Atheroscler Thromb 2021;28:1025-34. [PMID: 33191364 DOI: 10.5551/jat.58784] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Xu Z, Arnold M, Stevens D, Kaptoge S, Pennells L, Sweeting MJ, Barrett J, Di Angelantonio E, Wood AM. Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. Am J Epidemiol 2021;190:2000-14. [PMID: 33595074 DOI: 10.1093/aje/kwab031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
111 Brown R, Lewsey J, Wild S, Logue J, Welsh P. Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open 2021;11:e054893. [PMID: 34580105 DOI: 10.1136/bmjopen-2021-054893] [Reference Citation Analysis]
112 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC Scientific Document Group . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2021:zwab154. [PMID: 34558602 DOI: 10.1093/eurjpc/zwab154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
113 Verdickt S, Van der Schueren B, Vangoitsenhoven R, Descamps OS, Mertens A. Belgian data of ODYSSEY APPRISE: stringent LDL-c targets are in reach when using all available tools. Int J Clin Pract 2021;:e14916. [PMID: 34551183 DOI: 10.1111/ijcp.14916] [Reference Citation Analysis]
114 Pavlović J, Greenland P, Franco OH, Kavousi M, Ikram MK, Deckers JW, Ikram MA, Leening MJG. Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2021;14:e007183. [PMID: 34546786 DOI: 10.1161/CIRCOUTCOMES.120.007183] [Reference Citation Analysis]
115 Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol 2021;78:1210-22. [PMID: 34531021 DOI: 10.1016/j.jacc.2021.07.022] [Reference Citation Analysis]
116 Guo J, Wang A, Wang Y, Liu X, Zhang X, Wu S, Zhao X. Non-traditional Lipid Parameters as Potential Predictors of Asymptomatic Intracranial Arterial Stenosis. Front Neurol 2021;12:679415. [PMID: 34531811 DOI: 10.3389/fneur.2021.679415] [Reference Citation Analysis]
117 Jackson R, Wells S. Time to remove hypertension from our vocabulary? Lancet 2021;398:1023-5. [PMID: 34461041 DOI: 10.1016/S0140-6736(21)01916-4] [Reference Citation Analysis]
118 Santoleri F, Romagnoli A, Costantini A. Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study. Curr Med Res Opin 2021;37:2061-6. [PMID: 34515600 DOI: 10.1080/03007995.2021.1980777] [Reference Citation Analysis]
119 Huang Y, Tocmo R, Nauman MC, Haughan MA, Johnson JJ. Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells. Nutrients 2021;13:3156. [PMID: 34579033 DOI: 10.3390/nu13093156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Boettiger DC, Chattranukulchai P, Avihingsanon A, Chaiwarith R, Khusuwan S, Law MG, Ross J, Kiertiburanakul S. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS One 2021;16:e0256926. [PMID: 34499685 DOI: 10.1371/journal.pone.0256926] [Reference Citation Analysis]
121 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies., ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-337. [PMID: 34458905 DOI: 10.1093/eurheartj/ehab484] [Cited by in Crossref: 76] [Cited by in F6Publishing: 374] [Article Influence: 76.0] [Reference Citation Analysis]
122 Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Hildebrandt P, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FL, Catapano AL. Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus 2021;43:24-30. [DOI: 10.1016/j.athplu.2021.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Sweeney T, Quispe R, Das T, Juraschek SP, Martin SS, Michos ED. The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review. Expert Rev Precis Med Drug Dev 2021;6:247-58. [PMID: 34423130 DOI: 10.1080/23808993.2021.1930531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Di Minno A, Orsini RC, Chiesa M, Cavalca V, Calcaterra I, Tripaldella M, Anesi A, Fiorelli S, Eligini S, Colombo GI, Tremoli E, Porro B, Di Minno MND. Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach. Biomedicines 2021;9:1073. [PMID: 34440277 DOI: 10.3390/biomedicines9081073] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
125 Wang J, Dong PK, Xu XF, Huang T, Mao S, Wang QG, Hao J, Liu XH, Sun XD, Kang K, Zhang Q, Li JT, Wang T. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis. Curr Med Sci 2021;41:712-21. [PMID: 34403096 DOI: 10.1007/s11596-021-2406-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455-67. [PMID: 34120185 DOI: 10.1093/eurheartj/ehab312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
127 Lacaze P, Riaz M, Sebra R, Hooper AJ, Pang J, Tiller J, Polekhina G, Tonkin A, Reid C, Zoungas S, Murray AM, Nicholls S, Watts G, Schadt E, McNeil JJ. Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart 2021;8:e001710. [PMID: 34341098 DOI: 10.1136/openhrt-2021-001710] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Toth PP. Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. Am J Prev Cardiol 2021;6:100186. [PMID: 34327506 DOI: 10.1016/j.ajpc.2021.100186] [Reference Citation Analysis]
129 Salinero-Fort MA, Andrés-Rebollo FJS, Cárdenas-Valladolid J, Méndez-Bailón M, Chico-Moraleja RM, de Santa Pau EC, Jiménez-Trujillo I, Gómez-Campelo I, de Burgos Lunar C, de Miguel-Yanes JM; MADIABETES. Cardiovascular risk factors associated with acute myocardial infarction and stroke in the MADIABETES cohort. Sci Rep 2021;11:15245. [PMID: 34315938 DOI: 10.1038/s41598-021-94121-8] [Reference Citation Analysis]
130 Patel J, Pallazola VA, Dudum R, Greenland P, McEvoy JW, Blumenthal RS, Virani SS, Miedema MD, Shea S, Yeboah J, Abbate A, Hundley WG, Karger AB, Tsai MY, Sathiyakumar V, Ogunmoroti O, Cushman M, Savji N, Liu K, Nasir K, Blaha MJ, Martin SS, Al Rifai M. Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol 2021. [PMID: 34259820 DOI: 10.1001/jamacardio.2021.2321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
131 Liu J, Zhang B, Chen M, Zheng B. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in East Asian patients undergoing percutaneous coronary intervention: A meta-analysis of fifteen randomized controlled trials. Medicine (Baltimore) 2021;100:e26278. [PMID: 34160392 DOI: 10.1097/MD.0000000000026278] [Reference Citation Analysis]
132 Kocher J, Castellucci TB, Wen K, Li G, Yang X, Lei S, Jiang X, Yuan L. Simvastatin Reduces Protection and Intestinal T Cell Responses Induced by a Norovirus P Particle Vaccine in Gnotobiotic Pigs. Pathogens 2021;10:829. [PMID: 34357979 DOI: 10.3390/pathogens10070829] [Reference Citation Analysis]
133 Malmborg M, Schmiegelow MDS, Gerds T, Schou M, Kistorp C, Torp-Pedersen C, Gislason G. Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus. J Am Heart Assoc 2021;10:e020395. [PMID: 34151606 DOI: 10.1161/JAHA.120.020395] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open 2021;11:e043714. [PMID: 34130955 DOI: 10.1136/bmjopen-2020-043714] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
135 Szwed P, Gąsecka A, Zawadka M, Eyileten C, Postuła M, Mazurek T, Szarpak Ł, Filipiak KJ. Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications. J Clin Med 2021;10:2539. [PMID: 34201137 DOI: 10.3390/jcm10122539] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
136 Barale C, Melchionda E, Morotti A, Russo I. PCSK9 Biology and Its Role in Atherothrombosis. Int J Mol Sci 2021;22:5880. [PMID: 34070931 DOI: 10.3390/ijms22115880] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
137 Ji E, Lee S. Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases. Int J Mol Sci 2021;22:5770. [PMID: 34071276 DOI: 10.3390/ijms22115770] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
138 Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or Lipophilic Statins? Front Cardiovasc Med 2021;8:687585. [PMID: 34095267 DOI: 10.3389/fcvm.2021.687585] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
139 Occhipinti M, Brambilla M, Galli G, Manglaviti S, Giammaruco M, Prelaj A, Ferrara R, De Toma A, Proto C, Beninato T, Zattarin E, Lo Russo G, Gelibter AJ, Simmaco M, Preissner R, Garassino MC, De Braud F, Marchetti P. Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. J Pers Med 2021;11:424. [PMID: 34069851 DOI: 10.3390/jpm11050424] [Reference Citation Analysis]
140 Hopewell JC, Offer A, Haynes R, Bowman L, Li J, Chen F, Bulbulia R, Lathrop M, Baigent C, Landray MJ, Collins R, Armitage J, Parish S. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J 2020;41:3336-42. [PMID: 32702748 DOI: 10.1093/eurheartj/ehaa574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
141 Panajatovic MV, Singh F, Krähenbühl S, Bouitbir J. Effects of Simvastatin on Lipid Metabolism in Wild-Type Mice and Mice with Muscle PGC-1α Overexpression. Int J Mol Sci 2021;22:4950. [PMID: 34066911 DOI: 10.3390/ijms22094950] [Reference Citation Analysis]
142 Barankay I, Reese PP, Putt ME, Russell LB, Phillips C, Pagnotti D, Chadha S, Oyekanmi KO, Yan J, Zhu J, Volpp KG, Clapp JT. Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2021;4:e219211. [PMID: 33944923 DOI: 10.1001/jamanetworkopen.2021.9211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Phimarn W, Sungthong B, Itabe H. Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review. J Evid Based Integr Med 2021;26:2515690X211011038. [PMID: 33886393 DOI: 10.1177/2515690X211011038] [Reference Citation Analysis]
144 Ooi BNS, Raechell, Ying AF, Koh YZ, Jin Y, Yee SWL, Lee JHS, Chong SS, Tan JWC, Liu J, Lee CG, Drum CL. Robust Performance of Potentially Functional SNPs in Machine Learning Models for the Prediction of Atorvastatin-Induced Myalgia. Front Pharmacol 2021;12:605764. [PMID: 33967749 DOI: 10.3389/fphar.2021.605764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Cacciottolo PJ, Kostapanos MS, Hernan Sancho E, Pavey H, Kaloyirou F, Vamvaka E, Helmy J, Hubsch A, McEniery CM, Wilkinson IB, Cheriyan J. Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. BMJ Open 2021;11:e037457. [PMID: 33849844 DOI: 10.1136/bmjopen-2020-037457] [Reference Citation Analysis]
146 Zhang X, Peng X, Li L, Yu H, Yu B. Persistent Cigarette Smoking Attenuates Plaque Stabilization in Response to Lipid-Lowering Therapy: A Serial Optical Coherence Tomography Study. Front Cardiovasc Med 2021;8:616568. [PMID: 33859999 DOI: 10.3389/fcvm.2021.616568] [Reference Citation Analysis]
147 Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2021;3:CD012675. [PMID: 33769555 DOI: 10.1002/14651858.CD012675.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Yousufuddin M, Sharma UM, Bhagra S, Murad MH. Hyperlipidaemia and mortality among patients hospitalised with pneumonia: retrospective cohort and propensity score matched study. BMJ Open Respir Res 2021;8:e000757. [PMID: 33753360 DOI: 10.1136/bmjresp-2020-000757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Boettiger DC, Newall AT, Chattranukulchai P, Chaiwarith R, Khusuwan S, Avihingsanon A, Phillips A, Bendavid E, Law MG, Kahn JG, Ross J, Bautista-Arredondo S, Kiertiburanakul S. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. J Int AIDS Soc 2020;23 Suppl 1:e25494. [PMID: 32562359 DOI: 10.1002/jia2.25494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Chen N, Ren R, Wei X, Mukundan R, Li G, Xu X, Zhao G, Zhao Z, Lele SM, Reinhardt RA, Wang D. Thermoresponsive Hydrogel-Based Local Delivery of Simvastatin for the Treatment of Periodontitis. Mol Pharm 2021;18:1992-2003. [PMID: 33754729 DOI: 10.1021/acs.molpharmaceut.0c01196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Boettiger DC, Newall AT, Phillips A, Bendavid E, Law MG, Ryom L, Reiss P, Mocroft A, Bonnet F, Weber R, El-Sadr W, d'Arminio Monforte A, de Wit S, Pradier C, Hatleberg CI, Lundgren J, Sabin C, Kahn JG, Kazi DS. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. J Int AIDS Soc 2021;24:e25690. [PMID: 33749164 DOI: 10.1002/jia2.25690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
152 Phoon IKY, Koh YLE, Guo X, Usha S, Tan NC. Compatibility between an overnight fasting and random cholesterol tests in Asians. Sci Rep 2021;11:6478. [PMID: 33742059 DOI: 10.1038/s41598-021-85914-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Boettiger DC, Kerr S, Chattranukulchai P, Siwamogsatham S, Avihingsanon A. Maintenance of statin therapy among people living with HIV. AIDS 2021;35:567-74. [PMID: 33252492 DOI: 10.1097/QAD.0000000000002769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
154 Nozawa K, Higa S, Ii Y, Yamamoto Y, Asami Y. Antidyslipidemic Drug Prescriptions and Lipid Control Status After Unfavorable Annual Health Checkup Results: A Retrospective Cohort Study Using a Health Insurance Database. Drugs Real World Outcomes 2021;8:227-40. [PMID: 33751470 DOI: 10.1007/s40801-021-00231-0] [Reference Citation Analysis]
155 Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Canoy D, Dehghan A, Smith Byrne K, Bennett DA, Smith GD, Rahimi K. Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study. Genome Med 2021;13:38. [PMID: 33663581 DOI: 10.1186/s13073-021-00849-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
156 Temporelli PL, Arca M, D'Erasmo L, De Caterina R. Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible? J Clin Med 2021;10:886. [PMID: 33671688 DOI: 10.3390/jcm10040886] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
157 Zheng X, Shen S, Wang A, Zhu Z, Peng Y, Peng H, Zhong C, Guo D, Xu T, Chen J, Ju Z, Geng D, Zhang Y, He J. Angiopoietin-like protein 4 and clinical outcomes in ischemic stroke patients. Ann Clin Transl Neurol 2021;8:687-95. [PMID: 33616301 DOI: 10.1002/acn3.51319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Abdullah MMH, Vazquez-Vidal I, Baer DJ, House JD, Jones PJH, Desmarchelier C. Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence. Nutrients 2021;13:695. [PMID: 33671529 DOI: 10.3390/nu13020695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
159 Sá ACMGN, Machado ÍE, Bernal RTI, Malta DC. Factors associated with high LDL-Cholesterol in the Brazilian adult population: National Health Survey. Cien Saude Colet 2021;26:541-53. [PMID: 33605332 DOI: 10.1590/1413-81232021262.37102020] [Reference Citation Analysis]
160 Komiya I, Yamamoto A, Sunakawa S, Wakugami T. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study. Lipids Health Dis 2021;20:17. [PMID: 33610176 DOI: 10.1186/s12944-021-01434-8] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
161 Tam CHT, Lim CKP, Luk AOY, Ng ACW, Lee HM, Jiang G, Lau ESH, Fan B, Wan R, Kong APS, Tam WH, Ozaki R, Chow EYK, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JYY, Tsang MW, Kam G, Lau IT, Li JKY, Yeung VTF, Lau E, Lo S, Fung S, Cheng YL, Chow CC, Hu M, Yu W, Tsui SKW, Huang Y, Lan H, Szeto CC, Tang NLS, Ng MCY, So WY, Tomlinson B, Chan JCN, Ma RCW; Hong Kong Diabetes Register TRS Study Group., Hong Kong Diabetes Biobank Study Group. Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. Genome Med 2021;13:29. [PMID: 33608049 DOI: 10.1186/s13073-021-00831-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Jiang T, Xu C, Liu H, Liu M, Wang M, Jiang J, Zhang G, Yang C, Huang J, Lou Z. Linderae Radix Ethanol Extract Alleviates Diet-Induced Hyperlipidemia by Regulating Bile Acid Metabolism Through gut Microbiota. Front Pharmacol 2021;12:627920. [PMID: 33679408 DOI: 10.3389/fphar.2021.627920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
163 Joharatnam-Hogan N, Alexandre L, Yarmolinsky J, Lake B, Capps N, Martin RM, Ring A, Cafferty F, Langley RE. Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. Curr Oncol Rep 2021;23:29. [PMID: 33582975 DOI: 10.1007/s11912-021-01023-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
164 Zeitouni M, Nanna MG, Sun JL, Chiswell K, Peterson ED, Navar AM. Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. J Am Coll Cardiol 2020;76:653-64. [PMID: 32762899 DOI: 10.1016/j.jacc.2020.06.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
165 Mefford MT, Chen L, Lewis CE, Muntner P, Sidney S, Launer LJ, Monda KL, Ruzza A, Kassahun H, Rosenson RS, Carson AP. Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study. J Int Neuropsychol Soc 2021;27:1048-57. [PMID: 33563358 DOI: 10.1017/S1355617721000059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Blais JE, Tong GKY, Pathadka S, Mok M, Wong ICK, Chan EW. Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials. PLoS One 2021;16:e0246480. [PMID: 33561179 DOI: 10.1371/journal.pone.0246480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, Gibert C, Justice AC, Tate JP. Statin exposure and risk of cancer in people with and without HIV infection. AIDS 2021;35:325-34. [PMID: 33181533 DOI: 10.1097/QAD.0000000000002748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Ma J, Chen X. Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. Front Cardiovasc Med 2020;7:631398. [PMID: 33598482 DOI: 10.3389/fcvm.2020.631398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
169 Cardoso D, Medeiros G, Guim A, Azevedo P, Suassuna J, Lima Júnior D, Maciel M, Costa C, Lopes L, Silva J, Véras A, Carvalho F. Growth performance, carcass traits and meat quality of lambs fed with increasing levels of spineless cactus. Animal Feed Science and Technology 2021;272:114788. [DOI: 10.1016/j.anifeedsci.2020.114788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
170 Vuorio A, Kovanen PT. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond. Front Pharmacol 2020;11:579548. [PMID: 33542685 DOI: 10.3389/fphar.2020.579548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
171 Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. Open Heart 2020;7:e001396. [PMID: 33443127 DOI: 10.1136/openhrt-2020-001396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
172 Jung HH. Statin use and outcome risks according to predicted CVD risk in Korea: A retrospective cohort study. PLoS One 2021;16:e0245609. [PMID: 33450746 DOI: 10.1371/journal.pone.0245609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Huang W, Lim LMH, Aurangzeb AS, Wong CJ, Koh NSY, Huang Z, Teo HK, Chua TSJ, Tan SY. Performance of the coronary calcium score in an outpatient chest pain clinic and strategies for risk stratification. Clin Cardiol 2021;44:267-75. [PMID: 33434373 DOI: 10.1002/clc.23539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
174 Zhou Z, Ofori-Asenso R, Curtis AJ, Breslin M, Wolfe R, McNeil JJ, Murray AM, Ernst ME, Reid CM, Lockery JE, Woods RL, Tonkin AM, Nelson MR. Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. J Am Coll Cardiol 2020;76:17-27. [PMID: 32616158 DOI: 10.1016/j.jacc.2020.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
175 Jiang Y, Sun-Waterhouse D, Chen Y, Li F, Li D. Epigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars? Crit Rev Food Sci Nutr 2021;:1-19. [PMID: 33427492 DOI: 10.1080/10408398.2020.1870926] [Reference Citation Analysis]
176 Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na Nakorn C, Dejthevaporn C, Kroll MH. Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin. Pharmgenomics Pers Med 2021;14:1-13. [PMID: 33447072 DOI: 10.2147/PGPM.S278671] [Reference Citation Analysis]
177 Links TP, van der Boom T, Zandee WT, Lefrandt JD. Cardiovascular effects of overt and subclinical hyperthyroidism: focus on differentiated thyroid cancer. Endocr Connect 2021;10:R43-51. [PMID: 33320106 DOI: 10.1530/EC-20-0539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Banks E, Welsh J, Joshy G, Martin M, Paige E, Korda RJ. Comparison of cardiovascular disease risk factors, assessment and management in men and women, including consideration of absolute risk: a nationally representative cross-sectional study. BMJ Open 2020;10:e038761. [PMID: 33371018 DOI: 10.1136/bmjopen-2020-038761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
179 Kirsch F, Becker C, Kurz C, Schwettmann L, Schramm A. Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data. BMC Health Serv Res 2020;20:1145. [PMID: 33342431 DOI: 10.1186/s12913-020-05946-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Zhao X, Liu C, Zhou P, Sheng Z, Li J, Zhou J, Chen R, Wang Y, Chen Y, Song L, Zhao H, Yan H. Estimation of Major Adverse Cardiovascular Events in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Risk Prediction Score Model From a Derivation and Validation Study. Front Cardiovasc Med 2020;7:603621. [PMID: 33330667 DOI: 10.3389/fcvm.2020.603621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
181 Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020;324:2268-80. [PMID: 33190147 DOI: 10.1001/jama.2020.22258] [Cited by in Crossref: 232] [Cited by in F6Publishing: 220] [Article Influence: 116.0] [Reference Citation Analysis]
182 Gardouh AR, Nasef AM, Mostafa Y, Gad S. Design and evaluation of combined atorvastatin and ezetimibe optimized self- nano emulsifying drug delivery system. Journal of Drug Delivery Science and Technology 2020;60:102093. [DOI: 10.1016/j.jddst.2020.102093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
183 Chaure-Pardos A, Malo S, Rabanaque MJ, Arribas F, Moreno-Franco B, Aguilar-Palacio I. Factors Associated with the Prescribing of High-Intensity Statins. J Clin Med 2020;9:E3850. [PMID: 33260835 DOI: 10.3390/jcm9123850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Takaeko Y, Kajikawa M, Kishimoto S, Yamaji T, Harada T, Han Y, Kihara Y, Hida E, Chayama K, Goto C, Aibara Y, Yusoff FM, Maruhashi T, Nakashima A, Higashi Y. Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy. J Clin Med 2020;9:E3796. [PMID: 33255270 DOI: 10.3390/jcm9123796] [Reference Citation Analysis]
185 Gao M, Yu W, Hu H, Liu H, Fan K, Gu C, Wang L, Yu Y. Case Report: Cardiac Surgery and Combined Lipid-Lowering Drug Therapy for Homozygous Familial Hypercholesterolemia. Front Pediatr 2020;8:535949. [PMID: 33194883 DOI: 10.3389/fped.2020.535949] [Reference Citation Analysis]
186 White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J 2019;40:2801-9. [PMID: 31121022 DOI: 10.1093/eurheartj/ehz299] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
187 Doucas G, Liakos D, Koonin SD. The Effect of Lipectomy/Liposuction on Lipid Profiles in Antiretroviral Drug-induced Lipodystrophy Syndrome. Plast Reconstr Surg Glob Open 2020;8:e3171. [PMID: 33173685 DOI: 10.1097/GOX.0000000000003171] [Reference Citation Analysis]
188 Blais JE, Akyea RK, Coetzee A, Chan AH, Lau WC, Man KK, Harrison J, Chan EW, Beyene KA, Wong IC, Weng S. Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol. BJGP Open 2021;5:bjgpopen20X101127. [PMID: 33172851 DOI: 10.3399/bjgpopen20X101127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One 2020;15:e0241993. [PMID: 33166340 DOI: 10.1371/journal.pone.0241993] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
190 Almowallad S, Huwait E, Al-Massabi R, Saddeek S, Gauthaman K, Prola A. Punicalagin Regulates Key Processes Associated with Atherosclerosis in THP-1 Cellular Model. Pharmaceuticals (Basel) 2020;13:E372. [PMID: 33171640 DOI: 10.3390/ph13110372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
191 Patel AP, Wang (汪敏先) M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol 2021;41:465-74. [PMID: 33115266 DOI: 10.1161/ATVBAHA.120.315291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
192 Sozzi FB, Belmonte M, Schiavone M, Canetta C, Gupta R, Blasi F. Women’s Cardiac Health in 2020: A Systematic Review. Journal of Cardiac Critical Care TSS 2020;4:104-10. [DOI: 10.1055/s-0040-1718503] [Reference Citation Analysis]
193 Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2020;10:CD011748. [PMID: 33078867 DOI: 10.1002/14651858.CD011748.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
194 Pei L, Xiao H, Lai F, Li Z, Li Z, Yue S, Chen H, Li Y, Cao X. Early postpartum dyslipidemia and its potential predictors during pregnancy in women with a history of gestational diabetes mellitus. Lipids Health Dis 2020;19:220. [PMID: 33036614 DOI: 10.1186/s12944-020-01398-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
195 Hammam N, Abdel-Wahab N, Gheita TA. Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease. Curr Rheumatol Rev 2021;17:122-30. [PMID: 33030132 DOI: 10.2174/1573397116666201007123403] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Cho KH, Jeong MH. Clinical Benefit of Statins in Korean Patients with Acute Myocardial Infarction: Experience of the Korea Acute Myocardial Infarction Registry. J Lipid Atheroscler 2020;9:362-79. [PMID: 33024731 DOI: 10.12997/jla.2020.9.3.362] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Chaudhuri A. Frontiers in Lipid Lowering Therapy: To Statins and Beyond. Eur J Vasc Endovasc Surg 2020;60:798-9. [PMID: 33004279 DOI: 10.1016/j.ejvs.2020.08.051] [Reference Citation Analysis]
198 Barankay I, Reese PP, Putt ME, Russell LB, Loewenstein G, Pagnotti D, Yan J, Zhu J, McGilloway R, Brennan T, Finnerty D, Hoffer K, Chadha S, Volpp KG. Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial. JAMA Netw Open 2020;3:e2019429. [PMID: 33034639 DOI: 10.1001/jamanetworkopen.2020.19429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
199 Nesti L, Mengozzi A, Natali A. Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective. Am J Cardiovasc Drugs 2020;20:405-12. [PMID: 31840213 DOI: 10.1007/s40256-019-00391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Tunoa JA, Billups SJ, Lowe RN, Saseen JJ. Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. J Clin Lipidol 2020;14:784-90. [PMID: 32978094 DOI: 10.1016/j.jacl.2020.09.001] [Reference Citation Analysis]
201 Suero-Abreu GA, Karatasakis A, Rashid S, Tysarowski M, Douglas A, Patel R, Siddiqui E, Bhardwaj A, Gerula CM, Matassa D. Factors Associated with Disparities in Appropriate Statin Therapy in an Outpatient Inner City Population. Healthcare (Basel) 2020;8:E361. [PMID: 32987753 DOI: 10.3390/healthcare8040361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Chrysant SG, Chrysant GS. The Debate Over Egg Consumption and Incident Cardiovascular Disease. Cardiol Rev 2021;29:238-44. [PMID: 32956166 DOI: 10.1097/CRD.0000000000000325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Cho KH, Hong YJ. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives. Korean J Intern Med 2020;35:1045-58. [PMID: 32921006 DOI: 10.3904/kjim.2020.140] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
204 Sangaré MN, Baril JG, de Pokomandy A, Ferreira Guerra S, Carabali M, Laprise C, Thomas R, Klein M, Tremblay C, Roger M, Pexos C, Greenwald ZR, Machouf N, Durand M, Hardy I, Dakouo M, Trevisan A, Laporte L, Schnitzer ME, Trottier H. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data. Open Forum Infect Dis 2020;7:ofaa404. [PMID: 33204746 DOI: 10.1093/ofid/ofaa404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Pietraszek A. Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. Curr Drug Saf 2021;16:32-51. [PMID: 32881674 DOI: 10.2174/1574886315666200902154736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Weintraub WS, Arbab-Zadeh A. Should We Adjust Low-Density Lipoprotein Cholesterol Management to the Severity of Coronary Artery Disease? JACC Cardiovasc Imaging 2020;13:1973-5. [PMID: 32563657 DOI: 10.1016/j.jcmg.2020.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Charla E, Mercer J, Maffia P, Nicklin SA. Extracellular vesicle signalling in atherosclerosis. Cell Signal 2020;75:109751. [PMID: 32860954 DOI: 10.1016/j.cellsig.2020.109751] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
208 Mizus MC, Tiniakou E. Lipid-lowering Therapies in Myositis. Curr Rheumatol Rep 2020;22:70. [PMID: 32845379 DOI: 10.1007/s11926-020-00942-3] [Reference Citation Analysis]
209 Engeda JC, Lhachimi SK, Rosamond WD, Lund JL, Keyserling TC, Safford MM, Colantonio LD, Muntner P, Avery CL, Aminde L. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study. PLoS Med 2020;17:e1003280. [DOI: 10.1371/journal.pmed.1003280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
210 Marrs JC, Anderson SL. Bempedoic acid for the treatment of dyslipidemia. Drugs Context 2020;9:2020-6-5. [PMID: 32922503 DOI: 10.7573/dic.2020-6-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
211 Dakin HA, Farmer A, Gray AM, Holman RR. Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. Value Health 2020;23:1340-8. [PMID: 33032778 DOI: 10.1016/j.jval.2020.05.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Guo Y, Li Y, Liu X, Cui Y, Zhao Y, Sun S, Jia Q, Chai Q, Gong G, Zhang H, Liu Z. Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age. BMC Geriatr 2020;20:292. [PMID: 32807086 DOI: 10.1186/s12877-020-01682-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
213 Basman C, Fishman SL, Avtanski D, Rashid U, Kodra A, Chen K, Jonas R, Stoffels GJ, Lesser M, Inlall D, Ziskovich K, Singh V, Poretsky L. Glycosylated hemoglobin, but not advanced glycation end products, predicts severity of coronary artery disease in patients with or without diabetes. Metabol Open 2020;7:100050. [PMID: 32924001 DOI: 10.1016/j.metop.2020.100050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
214 Gold ME, Nanna MG, Doerfler SM, Schibler T, Wojdyla D, Peterson ED, Navar AM. Prevalence, treatment, and control of severe hyperlipidemia. Am J Prev Cardiol 2020;3:100079. [PMID: 34327462 DOI: 10.1016/j.ajpc.2020.100079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Pedro-Botet J, López-Miranda J, Badimón L, Civeira F, Guijarro C, Millán J, Mostaza JM, Pintó X, Valdivielso P, Masana L; Expert group from the Spanish Arteriosclerosis Society. Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. Am J Cardiovasc Drugs 2020;20:325-32. [PMID: 31650523 DOI: 10.1007/s40256-019-00376-y] [Reference Citation Analysis]
216 Aguirre Rodríguez JC. ¿116? ¿Hasta cuánto hay que bajar el cLDL de la población catalogada como en «bajo riesgo»? Revista Española de Cardiología 2020;73:690-1. [DOI: 10.1016/j.recesp.2020.03.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Vattimo ACA, Fonseca FAH, Morais DC, Generoso LF, Herrera R, Barbosa CM, de Oliveira Izar MC, Cardoso RA, Zung S. Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. Curr Ther Res Clin Exp 2020;93:100595. [PMID: 32904162 DOI: 10.1016/j.curtheres.2020.100595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
218 Everett BM, Moorthy MV, Tikkanen JT, Cook NR, Albert CM. Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. Circulation 2020;142:1148-58. [PMID: 32700639 DOI: 10.1161/CIRCULATIONAHA.120.046947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
219 Mortensen MB, Nordestgaard BG. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol 2019;4:1131-8. [PMID: 31577339 DOI: 10.1001/jamacardio.2019.3665] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
220 Zhu B, Wang J, Chen K, Yan W, Wang A, Wang W, Gao Z, Tang X, Yan L, Wan Q, Luo Z, Qin G, Chen L, Mu Y. A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study. Cardiovasc Diabetol 2020;19:112. [PMID: 32664945 DOI: 10.1186/s12933-020-01077-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
221 NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol 2020;49:173-92. [PMID: 31321439 DOI: 10.1093/ije/dyz099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
222 Poznyak AV, Grechko AV, Orekhova VA, Khotina V, Ivanova EA, Orekhov AN. NADPH Oxidases and Their Role in Atherosclerosis. Biomedicines 2020;8:E206. [PMID: 32664404 DOI: 10.3390/biomedicines8070206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
223 Pasta A, Formisano E, Cremonini AL, Maganza E, Parodi E, Piras S, Pisciotta L. Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis. Nutrients 2020;12:E2056. [PMID: 32664400 DOI: 10.3390/nu12072056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
224 Kohli-Lynch CN, Bellows BK, Thanassoulis G, Zhang Y, Pletcher MJ, Vittinghoff E, Pencina MJ, Kazi D, Sniderman AD, Moran AE. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiol 2019;4:969-77. [PMID: 31461121 DOI: 10.1001/jamacardio.2019.2851] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
225 Meier R, Rachamin Y, Rosemann T, Markun S. The Impact of the 2019 European Guideline for Cardiovascular Risk Management: A Cross-Sectional Study in General Practice. J Clin Med 2020;9:E2140. [PMID: 32645925 DOI: 10.3390/jcm9072140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
226 Qiu W, Chen J, Huang X, Guo J. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study. Lipids Health Dis 2020;19:163. [PMID: 32631347 DOI: 10.1186/s12944-020-01340-5] [Reference Citation Analysis]
227 Yang YS, Lee SY, Kim JS, Choi KM, Lee KW, Lee SC, Cho JR, Oh SJ, Kim JH, Choi SH. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. Endocrinol Metab (Seoul) 2020;35:367-76. [PMID: 32615721 DOI: 10.3803/EnM.2020.35.2.367] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
228 Butalia S, Lee-Krueger RCW, McBrien KA, Leung AAC, Anderson TJ, Quan H, Naugler C, Chen G, Campbell DJT. Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. CJC Open 2020;2:530-8. [PMID: 33305213 DOI: 10.1016/j.cjco.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
229 Podzolkov VI, Pisarev MV. Role of omega-3 polyunsaturated fatty acids in cardiovascular risk management. Cardiovasc Ther Prev 2020;19:2589. [DOI: 10.15829/1728-8800-2020-2589] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Climent E, Benaiges D, Pedro-Botet J. Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. Clin Investig Arterioscler 2020;32:175-82. [PMID: 32035666 DOI: 10.1016/j.arteri.2019.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Pradhan A, Bhandari M, Sethi R. Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. Cardiol Res Pract 2020;2020:9815016. [PMID: 32670636 DOI: 10.1155/2020/9815016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
232 Wang M, Liu J, Bellows BK, Qi Y, Sun J, Liu J, Moran AE, Zhao D. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease. Glob Heart 2020;15:43. [PMID: 32923337 DOI: 10.5334/gh.830] [Reference Citation Analysis]
233 Tan A, Fraser C, Khoo P, Watson S, Ooi K. Statins in Neuro-ophthalmology. Neuroophthalmology 2021;45:219-37. [PMID: 34366510 DOI: 10.1080/01658107.2020.1755872] [Reference Citation Analysis]
234 Koren MJ, Jones PH, Robinson JG, Sullivan D, Cho L, Hucko T, Lopez JAG, Fleishman AN, Somaratne R, Stroes E. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiol Ther 2020;9:447-65. [PMID: 32564340 DOI: 10.1007/s40119-020-00181-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Enas EA, Varkey B, Gupta R. Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals. Indian Heart J 2020;72:65-9. [PMID: 32534692 DOI: 10.1016/j.ihj.2020.03.015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Irawati S, Prayudeni S, Rachmawati R, Wita IW, Willfert B, Hak E, Taxis K. Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary healthcare facilities in Indonesia. BMJ Open 2020;10:e035098. [PMID: 32540888 DOI: 10.1136/bmjopen-2019-035098] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
237 Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, Weber C, Evans PC. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovasc Res 2019;115:1385-92. [PMID: 31228191 DOI: 10.1093/cvr/cvz166] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
238 Hu X, Zhuang XD, Mei WY, Liu G, Du ZM, Liao XX, Li Y. Exploring the causal pathway from body mass index to coronary heart disease: a network Mendelian randomization study. Ther Adv Chronic Dis 2020;11:2040622320909040. [PMID: 32523662 DOI: 10.1177/2040622320909040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
239 Tan YD, Xiao P, Guda C. In-depth Mendelian randomization analysis of causal factors for coronary artery disease. Sci Rep 2020;10:9208. [PMID: 32514076 DOI: 10.1038/s41598-020-66027-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
240 Bødtker H, Gunnersen S, Adelborg K, Kulenovic I, Kanstrup H, Falk E, Bruun JM, Mortensen MB. Association between lipid fractions and age of first myocardial infarction. Scand Cardiovasc J 2020;54:346-51. [PMID: 32483990 DOI: 10.1080/14017431.2020.1770850] [Reference Citation Analysis]
241 Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 2020;16:361-79. [PMID: 32494054 DOI: 10.1038/s41584-020-0428-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
242 Kim EJ, Wierzbicki AS. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Ther Adv Chronic Dis 2020;11:2040622320924569. [PMID: 32537117 DOI: 10.1177/2040622320924569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
243 Zhou XH, Cai LY, Lai WH, Bai X, Liu YB, Zhu Q, He GD, Chen JY, Huang M, Zhou ZL, Zhong SL. Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease. Front Pharmacol 2020;11:675. [PMID: 32536863 DOI: 10.3389/fphar.2020.00675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Na E, Cho S, Kim DJ, Choi J, Han E. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol 2020;19:67. [PMID: 32416728 DOI: 10.1186/s12933-020-01037-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
245 . Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). Revista Española de Cardiología 2020;73:404.e1-404.e59. [DOI: 10.1016/j.recesp.2019.11.024] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Teramoto T, Shibata H, Suzaki Y, Matsui S, Uemura N, Tomiyama H, Yamashina A. Discrepancy Between Fasting Flow-Mediated Dilation and Parameter of Lipids in Blood: A Randomized Exploratory Study of the Effect of Omega-3 Fatty Acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia. Adv Ther 2020;37:2169-83. [PMID: 32200533 DOI: 10.1007/s12325-020-01286-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
247 Shiffman D, Louie JZ, Devlin JJ, Knowles JW, McPhaul MJ. Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care. J Am Heart Assoc 2020;9:e015807. [PMID: 32319337 DOI: 10.1161/JAHA.119.015807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
248 Ingersgaard MV, Helms Andersen T, Norgaard O, Grabowski D, Olesen K. Reasons for Nonadherence to Statins - A Systematic Review of Reviews. Patient Prefer Adherence 2020;14:675-91. [PMID: 32308373 DOI: 10.2147/PPA.S245365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
249 Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation 2020;141:1600-7. [PMID: 32223429 DOI: 10.1161/CIRCULATIONAHA.120.046397] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 13.5] [Reference Citation Analysis]
250 Richards A, Jackson NJ, Cheng EM, Bryg RJ, Brown A, Towfighi A, Sanossian N, Barry F, Li N, Vickrey BG. Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk. Stroke 2020;51:1563-9. [PMID: 32200759 DOI: 10.1161/STROKEAHA.119.027160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, Holmes MV. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med 2020;17:e1003062. [PMID: 32203549 DOI: 10.1371/journal.pmed.1003062] [Cited by in Crossref: 95] [Cited by in F6Publishing: 128] [Article Influence: 47.5] [Reference Citation Analysis]
252 Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ? Int J Angiol 2020;29:2-11. [PMID: 32132810 DOI: 10.1055/s-0040-1701639] [Reference Citation Analysis]
253 Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ? Int J Angiol 2020;29:2-11. [PMID: 32132810 DOI: 10.1055/s-0040-1701639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
254 Sidebottom AC, Vacquier MC, Jensen JC, Bradley SM, Knickelbine T, Strauss C, Miedema MD. Trends in prevalence of guideline-based use of lipid-lowering therapy in a large health system. Clin Cardiol 2020;43:560-7. [PMID: 32104922 DOI: 10.1002/clc.23347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
255 Tudor K, Brooks J, Howick J, Fox R, Aveyard P. Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence. BMJ Open 2020;10:e033070. [PMID: 32051312 DOI: 10.1136/bmjopen-2019-033070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
256 Masson W, Huerín M, Lobo LM, Masson G, Molinero G, Nemec M, Boccadoro M, Romero C, Micali G, Siniawski D. Impact of the 2019 European Guidelines on Diabetes in Clinical Practice: Real and Simulated Analyses of Lipid Goals. J Cardiovasc Dev Dis 2020;7:E6. [PMID: 32033316 DOI: 10.3390/jcdd7010006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Tralhão A, Póvoa P. Cardiovascular Events After Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies. J Clin Med 2020;9:E414. [PMID: 32028660 DOI: 10.3390/jcm9020414] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
258 Dalton JE, Rothberg MB, Dawson NV, Krieger NI, Zidar DA, Perzynski AT. Failure of Traditional Risk Factors to Adequately Predict Cardiovascular Events in Older Populations. J Am Geriatr Soc 2020;68:754-61. [PMID: 31958154 DOI: 10.1111/jgs.16329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
259 Ferrari D, Motta A, Strollo M, Locatelli M. Retrospective analysis of the cholesterol levels in a European mid-latitude population between 2007 and 2018: controversies and therapeutic implications. Acta Biomed 2020;91:e2020063. [PMID: 32921759 DOI: 10.23750/abm.v91i3.8980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Weng S, Luo Y, Zhang Z, Su X, Peng D. Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials. Endocrine 2020;67:305-17. [PMID: 31950354 DOI: 10.1007/s12020-020-02190-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
261 Turner RM, Fontana V, FitzGerald R, Morris AP, Pirmohamed M. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. Br J Clin Pharmacol 2020;86:62-74. [PMID: 31656041 DOI: 10.1111/bcp.14133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
262 Alexandre L, Clark AB, Walton S, Lewis MP, Kumar B, Cheong EC, Warren H, Kadirkamanathan SS, Parsons SL, Dresner SM, Sims E, Jones M, Hammond M, Flather M, Loke YK, Swart AM, Hart AR. Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study. BJS Open 2020;4:59-70. [PMID: 32011825 DOI: 10.1002/bjs5.50239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
263 Schade DS, Eaton RP. A Simplified Approach to Reducing Cardiovascular Risk. J Clin Endocrinol Metab 2019;104:6033-9. [PMID: 30785997 DOI: 10.1210/jc.2018-02509] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Kleipool EE, Dorresteijn JA, Smulders YM, Visseren FL, Peters MJ, Muller M. Treatment of hypercholesterolaemia in older adults calls for a patient-centred approach. Heart 2020;106:261-6. [PMID: 31780523 DOI: 10.1136/heartjnl-2019-315600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
265 Tkachova O, Iakovlieva L, Mitkova Z, Manova M, Savova A, Petrova G. Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. BMC Health Serv Res 2019;19:902. [PMID: 31775736 DOI: 10.1186/s12913-019-4736-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
266 Trevisi L, Orav JE, Atwood S, Brown C, Curley C, King C, Muskett O, Sehn H, Nelson KA, Begay MG, Shin SS. Integrating community health representatives with health care systems: clinical outcomes among individuals with diabetes in Navajo Nation. Int J Equity Health 2019;18:183. [PMID: 31771603 DOI: 10.1186/s12939-019-1097-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
267 Atkins PW, Perez HA, Spence JD, Muñoz SE, Armando LJ, García NH. Increased carotid plaque burden in patients with family medical history of premature cardiovascular events in the absence of classical risk factors. Arch Med Sci 2019;15:1388-96. [PMID: 31749866 DOI: 10.5114/aoms.2019.84677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Allara E, Morani G, Carter P, Gkatzionis A, Zuber V, Foley CN, Rees JMB, Mason AM, Bell S, Gill D, Lindström S, Butterworth AS, Di Angelantonio E, Peters J, Burgess S; INVENT consortium. Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation. Circ Genom Precis Med 2019;12:e002711. [PMID: 31756303 DOI: 10.1161/CIRCGEN.119.002711] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 10.7] [Reference Citation Analysis]
269 Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res 2019;124:315-27. [PMID: 30653442 DOI: 10.1161/CIRCRESAHA.118.313591] [Cited by in Crossref: 214] [Cited by in F6Publishing: 416] [Article Influence: 71.3] [Reference Citation Analysis]
270 Leening MJG, Cook NR, Franco OH, Manson JE, Lakshminarayan K, LaMonte MJ, Leira EC, Robinson JG, Ridker PM, Paynter NP. Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. J Am Heart Assoc 2018;7:e007514. [PMID: 30371339 DOI: 10.1161/JAHA.117.007514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
271 Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M. Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated. J Am Heart Assoc 2018;7:e010049. [PMID: 30371337 DOI: 10.1161/JAHA.118.010049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
272 Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, Mair FS, Guthrie B, Wild S, McAllister DA. Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. BMC Med 2019;17:201. [PMID: 31711480 DOI: 10.1186/s12916-019-1427-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
273 Robinson JG, Williams KJ, Gidding S, Borén J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybjærg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. J Am Heart Assoc 2018;7:e009778. [PMID: 30371276 DOI: 10.1161/JAHA.118.009778] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
274 Elgendy IY, Nadeau SE, Bairey Merz CN, Pepine CJ; American College of Cardiology Cardiovascular Disease in Women Committee †., American College of Cardiology Cardiovascular Disease in Women Committee. Migraine Headache: An Under-Appreciated Risk Factor for Cardiovascular Disease in Women. J Am Heart Assoc 2019;8:e014546. [PMID: 31707945 DOI: 10.1161/JAHA.119.014546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
275 Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D, Yue W, Yan F, Wang Z, Lu Z. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health 2019;19:1500. [PMID: 31711454 DOI: 10.1186/s12889-019-7827-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
276 Marchal S, Hollander M, Schoenmakers M, Schouwink M, Timmer JR, Bilo HJG, Schwantje O, van 't Hof AWJ, Hoes AW. Design of the ZWOT-CASE study: an observational study on the effectiveness of an integrated programme for cardiovascular risk management compared to usual care in general practice. BMC Fam Pract 2019;20:149. [PMID: 31675925 DOI: 10.1186/s12875-019-1039-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, Assimes TL, Huang J, Min Lee K, Shao Q, Huffman JE, Kabrhel C, Huang Y, Sun YV, Vujkovic M, Saleheen D, Miller DR, Reaven P, DuVall S, Boden WE, Pyarajan S, Reiner AP, Trégouët DA, Henke P, Kooperberg C, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, Smith NL, O'Donnell CJ, Tsao PS, Kathiresan S, Obi A, Damrauer SM, Natarajan P; INVENT Consortium., Veterans Affairs’ Million Veteran Program. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019;51:1574-9. [PMID: 31676865 DOI: 10.1038/s41588-019-0519-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 56] [Article Influence: 11.7] [Reference Citation Analysis]
278 Peradze N, Farr OM, Perakakis N, Lázaro I, Sala-Vila A, Mantzoros CS. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc Diabetol 2019;18:141. [PMID: 31672146 DOI: 10.1186/s12933-019-0945-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
279 Nanna MG, Peterson ED, Wojdyla D, Navar AM. The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. J Gen Intern Med 2020;35:1701-8. [PMID: 31667745 DOI: 10.1007/s11606-019-05361-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
280 Brotons Cuixart C, Alemán Sánchez JJ, Banegas Banegas JR, Fondón León C, Lobos-Bejarano JM, Martín Rioboó E, Navarro Pérez J, Orozco-Beltrán D, Villar Álvarez F; Grupo de Prevención Cardiovascular del PAPPS. Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2018. Aten Primaria 2018;50 Suppl 1:4-28. [PMID: 29866357 DOI: 10.1016/S0212-6567(18)30360-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
281 Nanna MG, Navar AM, Zakroysky P, Xiang Q, Goldberg AC, Robinson J, Roger VL, Virani SS, Wilson PWF, Elassal J, Lee LV, Wang TY, Peterson ED. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol 2018;3:739-48. [PMID: 29898219 DOI: 10.1001/jamacardio.2018.1511] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 13.0] [Reference Citation Analysis]
282 Wilkins JT, Gidding SS, Robinson JG. Can atherosclerosis be cured? Curr Opin Lipidol 2019;30:477-84. [PMID: 31592794 DOI: 10.1097/MOL.0000000000000644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
283 Kostapanos MS, Cacciottolo PJ, Hubsch A, Pavey H, Hurlock J, Maki-Petaja K, Wilkinson IB, Cheriyan J. Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers - a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. J Drug Assess 2019;8:167-74. [PMID: 31692938 DOI: 10.1080/21556660.2019.1677673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
284 Watanabe Y, Tatsuno I. Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. J Atheroscler Thromb 2020;27:183-98. [PMID: 31582621 DOI: 10.5551/jat.50658] [Cited by in Crossref: 12] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
285 Wolf D, Ley K. [Immunity and inflammation in atherosclerosis]. Herz 2019;44:107-20. [PMID: 30859253 DOI: 10.1007/s00059-019-4790-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
286 Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol 2018;3:619-27. [PMID: 29926099 DOI: 10.1001/jamacardio.2018.1470] [Cited by in Crossref: 200] [Cited by in F6Publishing: 235] [Article Influence: 66.7] [Reference Citation Analysis]
287 Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, White C, Blot WJ, Wang TJ. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med 2019;381:1114-23. [PMID: 31532959 DOI: 10.1056/NEJMoa1815359] [Cited by in Crossref: 55] [Cited by in F6Publishing: 69] [Article Influence: 18.3] [Reference Citation Analysis]
288 Tuttolomondo A, Simonetta I, Daidone M, Mogavero A, Ortello A, Pinto A. Metabolic and Vascular Effect of the Mediterranean Diet. Int J Mol Sci. 2019;20:4716. [PMID: 31547615 DOI: 10.3390/ijms20194716] [Cited by in Crossref: 38] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
289 Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res 2018;122:1420-38. [PMID: 29748367 DOI: 10.1161/CIRCRESAHA.118.311227] [Cited by in Crossref: 94] [Cited by in F6Publishing: 109] [Article Influence: 31.3] [Reference Citation Analysis]
290 Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Intern Med 2018;178:1224-9. [PMID: 30073275 DOI: 10.1001/jamainternmed.2018.2859] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
291 Berkowitz SA, Sussman JB, Jonas DE, Basu S. Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus. J Am Coll Cardiol 2018;72:1214-23. [PMID: 30189998 DOI: 10.1016/j.jacc.2018.07.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
292 Ju A, Hanson CS, Banks E, Korda R, Craig JC, Usherwood T, MacDonald P, Tong A. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018;68:e408-19. [PMID: 29784867 DOI: 10.3399/bjgp18X696365] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
293 Guiné RPF, Fontes L, Lima MJ. Evaluation of texture in Serra da Estrela cheese manufactured in different dairies. Open Agriculture 2019;4:475-86. [DOI: 10.1515/opag-2019-0048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
294 Johnson D, Hughes D, Pirmohamed M, Jorgensen A. Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials. J Pers Med 2019;9:E42. [PMID: 31480618 DOI: 10.3390/jpm9030042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
295 Pan M, Deng Y, Zheng C, Nie H, Tang K, Zhang Y, Yang Q. The effects of Qigong exercises on blood lipid profiles of middle-aged and elderly individuals: A systematic review and network meta-analysis. European Journal of Integrative Medicine 2019;30:100950. [DOI: 10.1016/j.eujim.2019.100950] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
296 Shukla AK, Mehani R. Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. J Family Med Prim Care 2019;8:2249-57. [PMID: 31463238 DOI: 10.4103/jfmpc.jfmpc_406_19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
297 Alghamdi J, Matou-Nasri S, Alghamdi F, Alghamdi S, Alfadhel M, Padmanabhan S. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. Int J Neuropsychopharmacol 2018;21:1067-75. [PMID: 29986042 DOI: 10.1093/ijnp/pyy060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
298 Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, Lee CW. Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. BMC Cardiovasc Disord 2019;19:201. [PMID: 31426749 DOI: 10.1186/s12872-019-1184-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
299 Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Li Z, Peterson ED, Navar AM. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes 2019;12:e005562. [PMID: 31416347 DOI: 10.1161/CIRCOUTCOMES.118.005562] [Cited by in Crossref: 34] [Cited by in F6Publishing: 58] [Article Influence: 11.3] [Reference Citation Analysis]
300 Nanna MG, Navar AM, Wojdyla D, Peterson ED. The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. J Am Geriatr Soc 2019;67:2560-7. [PMID: 31411740 DOI: 10.1111/jgs.16123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
301 Larsen LB, Sondergaard J, Thomsen JL, Halling A, Sønderlund AL, Christensen JR, Thilsing T. Step-wise approach to prevention of chronic diseases in the Danish primary care sector with the use of a personal digital health profile and targeted follow-up - an assessment of attendance. BMC Public Health 2019;19:1092. [PMID: 31409343 DOI: 10.1186/s12889-019-7419-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
302 Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ, Choi S, Moon MK, Na JO, Park KY, Oh MS, Han SY, Noh J, Yi KH, Lee SH, Hong SC, Jeong IK; Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis. 2018 Guidelines for the Management of Dyslipidemia in Korea. J Lipid Atheroscler 2019;8:78-131. [PMID: 32821702 DOI: 10.12997/jla.2019.8.2.78] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
303 Nanna MG, Navar AM, Wang TY, Li S, Virani SS, Li Z, Robinson JG, Roger VL, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2019;214:113-24. [PMID: 31202098 DOI: 10.1016/j.ahj.2019.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
304 Ji S, Zhang B, Wang X, Shi H, Yu L, Wang X. Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis. Biosci Rep 2019;39:BSR20190180. [PMID: 31285388 DOI: 10.1042/BSR20190180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
305 Chen LW, Lin CS, Tsai MC, Shih SF, Lim ZW, Chen SJ, Tsui PF, Ho LJ, Lai JH, Liou JT. Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells. Int J Mol Sci 2019;20:E3534. [PMID: 31330988 DOI: 10.3390/ijms20143534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
306 Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, Guo Y, Xu X, Bian Z, Hu R, Walters RG, Chen J, Ala-Korpela M, Parish S, Clarke RJ, Peto R, Collins R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol 2018;71:620-32. [PMID: 29420958 DOI: 10.1016/j.jacc.2017.12.006] [Cited by in Crossref: 137] [Cited by in F6Publishing: 112] [Article Influence: 45.7] [Reference Citation Analysis]
307 Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts SABM, Lameijer M, Gijbels MJ, Beckers L, den Toom M, Slütter B, Kuiper J, Duchene J, Aslani M, Megens RTA, van 't Veer C, Kooij G, Schrijver R, Hoeksema MA, Boon L, Fay F, Tang J, Baxter S, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MPJ, Nicolaes GA, Mulder WJM, Weber C, Lutgens E. Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. J Am Coll Cardiol 2018;71:527-42. [PMID: 29406859 DOI: 10.1016/j.jacc.2017.11.055] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 24.0] [Reference Citation Analysis]
308 Jayawardana KS, Mundra PA, Giles C, Barlow CK, Nestel PJ, Barnes EH, Kirby A, Thompson P, Sullivan DR, Alshehry ZH, Mellett NA, Huynh K, McConville MJ, Zoungas S, Hillis GS, Chalmers J, Woodward M, Marschner IC, Wong G, Kingwell BA, Simes J, Tonkin AM, Meikle PJ; LIPID Study Investigators. Changes in plasma lipids predict pravastatin efficacy in secondary prevention. JCI Insight 2019;4:128438. [PMID: 31292301 DOI: 10.1172/jci.insight.128438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
309 Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ, Choi S, Moon MK, Na JO, Park KY, Oh MS, Han SY, Noh J, Yi KH, Lee SH, Hong SC, Jeong IK. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med 2019;34:723-71. [PMID: 31272142 DOI: 10.3904/kjim.2019.188] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 20.0] [Reference Citation Analysis]
310 Wu CY, Yu HS, Chai CY, Wen YH, Wu SS, Chang YP, Lin CR, Tsai JH. Increased ischemic stroke risk in patients with Behçet's disease: A nationwide population-based cohort study. PLoS One 2019;14:e0218652. [PMID: 31237911 DOI: 10.1371/journal.pone.0218652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
311 Katzmann JL, Laufs U. New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. Curr Cardiol Rep 2019;21:69. [PMID: 31227914 DOI: 10.1007/s11886-019-1159-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
312 Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet 2019;28:688-97. [PMID: 30445611 DOI: 10.1093/hmg/ddy384] [Cited by in Crossref: 41] [Cited by in F6Publishing: 58] [Article Influence: 13.7] [Reference Citation Analysis]
313 Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR, Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP, Sattar N, Welsh P. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation 2019;140:542-52. [PMID: 31216866 DOI: 10.1161/CIRCULATIONAHA.119.041149] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 15.7] [Reference Citation Analysis]
314 Boulet J, Peña J, Hulten EA, Neilan TG, Dragomir A, Freeman C, Lambert C, Hijal T, Nadeau L, Brophy JM, Mousavi N. Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck. J Am Heart Assoc 2019;8:e005996. [PMID: 31213106 DOI: 10.1161/JAHA.117.005996] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
315 Pluijmert NJ, den Haan MC, van Zuylen VL, Steendijk P, de Boer HC, van Zonneveld AJ, Fibbe WE, Schalij MJ, Quax PHA, Atsma DE. Hypercholesterolemia affects cardiac function, infarct size and inflammation in APOE*3-Leiden mice following myocardial ischemia-reperfusion injury. PLoS One 2019;14:e0217582. [PMID: 31199833 DOI: 10.1371/journal.pone.0217582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
316 Ekker MS, Verhoeven JI, Vaartjes I, Jolink WMT, Klijn CJM, de Leeuw FE. Association of Stroke Among Adults Aged 18 to 49 Years With Long-term Mortality. JAMA 2019;321:2113-23. [PMID: 31121602 DOI: 10.1001/jama.2019.6560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
317 Yandrapalli S, Gupta S, Andries G, Cooper HA, Aronow WS. Drug Therapy of Dyslipidemia in the Elderly. Drugs Aging 2019;36:321-40. [PMID: 30613912 DOI: 10.1007/s40266-018-00632-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
318 Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017;2:1069-78. [PMID: 28832867 DOI: 10.1001/jamacardio.2017.2762] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 28.7] [Reference Citation Analysis]
319 Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017;2:959-66. [PMID: 28768335 DOI: 10.1001/jamacardio.2017.2289] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 21.7] [Reference Citation Analysis]
320 Margerie D, Lefebvre P, Raverdy V, Schwahn U, Ruetten H, Larsen P, Duhamel A, Labreuche J, Thuillier D, Derudas B, Gheeraert C, Dehondt H, Dhalluin Q, Alexandre J, Caiazzo R, Nesslany P, Verkindt H, Pattou F, Staels B. Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. BMC Med Genomics 2019;12:80. [PMID: 31159817 DOI: 10.1186/s12920-019-0536-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
321 Zheng X, Han X, Xu H, Ai J, Yang L, Wei Q. Prognostic value of lipid profiles after radical prostatectomy: a systematic review and meta-analysis. Lipids Health Dis 2019;18:124. [PMID: 31138210 DOI: 10.1186/s12944-019-1068-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 Weintraub WS. Perspective on Trends in Statin Use. JAMA Cardiol 2017;2:11-2. [PMID: 27842177 DOI: 10.1001/jamacardio.2016.4710] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
323 Ko A, Choi S, Chang J, Park SM. Effect of Lipid-Testing Interval on Stoke Risk among Newly Diagnosed Dyslipidemia Patients Initiated on Statins. J Clin Med 2019;8:E742. [PMID: 31137637 DOI: 10.3390/jcm8050742] [Reference Citation Analysis]
324 Carbone S, Dixon DL, Buckley LF, Abbate A. Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. Mayo Clin Proc 2018;93:1629-47. [PMID: 30392544 DOI: 10.1016/j.mayocp.2018.07.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
325 Wang YX, Wang AP, Ye YN, Gao ZN, Tang XL, Yan L, Wan Q, Wang WQ, Luo ZJ, Qin GJ, Chen LL, Mu YM. Elevated triglycerides rather than other lipid parameters are associated with increased urinary albumin to creatinine ratio in the general population of China: a report from the REACTION study. Cardiovasc Diabetol 2019;18:57. [PMID: 31054570 DOI: 10.1186/s12933-019-0863-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
326 Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol 2019;18:54. [PMID: 31029144 DOI: 10.1186/s12933-019-0860-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
327 Byrne P, Cullinan J, Gillespie P, Perera R, Smith SM. Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort. Br J Gen Pract 2019;69:e373-80. [PMID: 31015226 DOI: 10.3399/bjgp19X702701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
328 Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open 2019;9:e023085. [PMID: 31015265 DOI: 10.1136/bmjopen-2018-023085] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
329 Kapila V, Jetty P, Basile VS, Dubois L. Management of transient ischemic attack or nondisabling stroke related to extracranial internal carotid artery stenosis. CMAJ 2019;191:E418-22. [PMID: 30988042 DOI: 10.1503/cmaj.180735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
330 Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019;105:975-81. [PMID: 30988003 DOI: 10.1136/heartjnl-2018-314253] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 14.0] [Reference Citation Analysis]
331 Wascher TC, Paulweber B, Toplak H, Saely CH, Drexel H, Föger B, Hoppichler F, Stulnig T, Stingl H, Clodi M; den Ausschuss Leitlinien. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)]. Wien Klin Wochenschr 2019;131:136-8. [PMID: 30980157 DOI: 10.1007/s00508-019-1444-2] [Reference Citation Analysis]
332 Rist PM, Buring JE, Ridker PM, Kase CS, Kurth T, Rexrode KM. Lipid levels and the risk of hemorrhagic stroke among women. Neurology 2019;92:e2286-94. [PMID: 30971484 DOI: 10.1212/WNL.0000000000007454] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
333 Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, Lund JL, Keyserling TC, Avery CL. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. Diabetes Res Clin Pract 2019;151:96-105. [PMID: 30954511 DOI: 10.1016/j.diabres.2019.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
334 Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. Mediators Inflamm 2019;2019:7434376. [PMID: 31089324 DOI: 10.1155/2019/7434376] [Cited by in Crossref: 22] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
335 Lowenstern A, Navar AM, Li S, Virani SS, Goldberg AC, Louie MJ, Lee LV, Peterson ED, Wang TY. Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry). Am J Cardiol 2019;123:1011-8. [PMID: 30660354 DOI: 10.1016/j.amjcard.2018.12.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
336 Jensen JS, Weeke PE, Bang LE, Høfsten DE, Ripa MS, Schjerning AM, Theilade JE, Køber LV, Gislason GH, Pallisgaard J. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. BMJ Open 2019;9:e022702. [PMID: 30940751 DOI: 10.1136/bmjopen-2018-022702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
337 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:e177-232. [PMID: 30894318 DOI: 10.1016/j.jacc.2019.03.010] [Cited by in Crossref: 365] [Cited by in F6Publishing: 311] [Article Influence: 121.7] [Reference Citation Analysis]
338 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1376-414. [PMID: 30894319 DOI: 10.1016/j.jacc.2019.03.009] [Cited by in Crossref: 314] [Cited by in F6Publishing: 287] [Article Influence: 104.7] [Reference Citation Analysis]
339 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596-646. [PMID: 30879355 DOI: 10.1161/CIR.0000000000000678] [Cited by in Crossref: 270] [Cited by in F6Publishing: 675] [Article Influence: 90.0] [Reference Citation Analysis]
340 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e563-95. [PMID: 30879339 DOI: 10.1161/CIR.0000000000000677] [Cited by in Crossref: 51] [Cited by in F6Publishing: 139] [Article Influence: 17.0] [Reference Citation Analysis]
341 Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord 2019;19:61. [PMID: 30876390 DOI: 10.1186/s12872-019-1034-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
342 Cimaglia P, Vieceli Dalla Sega F, Vitali F, Lodolini V, Bernucci D, Passarini G, Fortini F, Marracino L, Aquila G, Rizzo P, Ferrari R, Campo G. Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. Front Physiol 2019;10:217. [PMID: 30914970 DOI: 10.3389/fphys.2019.00217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
343 Tosti V, Bertozzi B, Fontana L. Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J Gerontol A Biol Sci Med Sci. 2018;73:318-326. [PMID: 29244059 DOI: 10.1093/gerona/glx227] [Cited by in Crossref: 167] [Cited by in F6Publishing: 214] [Article Influence: 55.7] [Reference Citation Analysis]
344 Noh M, Kwon H, Jung CH, Lee SW, Lee JY, Kim MJ, Han Y, Kwon TW, Cho YP. Impact of diabetes duration on heart failure in Korean patients without clinical cardiovascular disease. Medicine (Baltimore) 2019;98:e14742. [PMID: 30817631 DOI: 10.1097/MD.0000000000014742] [Reference Citation Analysis]
345 Riestenberg RA, Furman A, Cowen A, Pawlowksi A, Schneider D, Lewis AA, Kelly S, Taiwo B, Achenbach C, Palella F, Stone NJ, Lloyd-Jones DM, Feinstein MJ. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2019;209:79-87. [PMID: 30685678 DOI: 10.1016/j.ahj.2018.11.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
346 Ma Y, Rao J, Long J, Lin L, Liu J, Guo Z. [Correlation of lipoprotein(a) with clinical stability and severity of coronary artery lesions in patients with coronary artery disease]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:235-40. [PMID: 30890514 DOI: 10.12122/j.issn.1673-4254.2019.02.17] [Reference Citation Analysis]
347 Ke C, Gupta R, Xavier D, Prabhakaran D, Mathur P, Kalkonde YV, Kolpak P, Suraweera W, Jha P; Million Death Study Collaborators. Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study. Lancet Glob Health 2018;6:e914-23. [PMID: 30012272 DOI: 10.1016/S2214-109X(18)30242-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 10.7] [Reference Citation Analysis]
348 Han S, Zhang W, Zhang R, Jiao J, Fu C, Tong X, Zhang W, Qin L. Cereal fiber improves blood cholesterol profiles and modulates intestinal cholesterol metabolism in C57BL/6 mice fed a high-fat, high-cholesterol diet. Food Nutr Res 2019;63. [PMID: 30863273 DOI: 10.29219/fnr.v63.1591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
349 Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-15. [PMID: 30712900 DOI: 10.1016/S0140-6736(18)31942-1] [Cited by in Crossref: 245] [Cited by in F6Publishing: 274] [Article Influence: 81.7] [Reference Citation Analysis]
350 Valdes-Marquez E, Parish S, Clarke R, Stari T, Worrall BB, Hopewell JC; METASTROKE Consortium of the ISGC,. Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study. Neurology 2019;92:e1176-87. [PMID: 30787162 DOI: 10.1212/WNL.0000000000007091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
351 Yi SW, Yi JJ, Ohrr H. Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. Sci Rep 2019;9:1596. [PMID: 30733566 DOI: 10.1038/s41598-018-38461-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
352 Ribas N, Recasens L, Pérez S, Bazán V, Pedro-Botet J, Ruiz S, Elosua R, Martí-Almor J. A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. Clin Investig Arterioscler 2019;31:93-100. [PMID: 30711338 DOI: 10.1016/j.arteri.2018.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
353 Taylor K, Davey Smith G, Relton CL, Gaunt TR, Richardson TG. Prioritizing putative influential genes in cardiovascular disease susceptibility by applying tissue-specific Mendelian randomization. Genome Med 2019;11:6. [PMID: 30704512 DOI: 10.1186/s13073-019-0613-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
354 José Gagliardino J, Arechavaleta R, Goldberg Eliaschewitz F, Iglay K, Brodovicz K, Gonzalez CD, Yu S, Ravi Shankar R, Heisel O, Keown P, Tunceli K. Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes. J Clin Transl Endocrinol 2019;15:76-80. [PMID: 30788219 DOI: 10.1016/j.jcte.2019.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
355 Woringer M, Dharmayat KI, Greenfield G, Bottle A, Ray KK. American Heart Association's Cholesterol CarePlan as a Smartphone-Delivered Web App for Patients Prescribed Cholesterol-Lowering Medication: Protocol for an Observational Feasibility Study. JMIR Res Protoc 2019;8:e9017. [PMID: 30679150 DOI: 10.2196/resprot.9017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
356 Xia DK, Hu ZG, Tian YF, Zeng FJ. Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials. Drug Des Devel Ther 2019;13:405-22. [PMID: 30774306 DOI: 10.2147/DDDT.S187690] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
357 Kaiser P, Arnold AM, Benkeser D, Zeki Al Hazzouri A, Hirsch CH, Psaty BM, Odden MC. Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort. Int J Epidemiol 2018;47:246-54. [PMID: 29024975 DOI: 10.1093/ije/dyx179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
358 Zheng J, Sun Z, Zhang X, Li Z, Guo X, Xie Y, Sun Y, Zheng L. Non-traditional lipid profiles associated with ischemic stroke not hemorrhagic stroke in hypertensive patients: results from an 8.4 years follow-up study. Lipids Health Dis 2019;18:9. [PMID: 30621696 DOI: 10.1186/s12944-019-0958-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
359 American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S103-23. [PMID: 30559236 DOI: 10.2337/dc19-S010] [Cited by in Crossref: 304] [Cited by in F6Publishing: 269] [Article Influence: 76.0] [Reference Citation Analysis]
360 Kini V, Ho PM. Interventions to Improve Medication Adherence: A Review. JAMA 2018;320:2461-73. [PMID: 30561486 DOI: 10.1001/jama.2018.19271] [Cited by in Crossref: 187] [Cited by in F6Publishing: 150] [Article Influence: 46.8] [Reference Citation Analysis]
361 Boklage SH, Malangone-Monaco E, Lopez-Gonzalez L, Ding Y, Henriques C, Elassal J. Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions. Cardiovasc Drugs Ther. 2018;32:273-280. [PMID: 29855748 DOI: 10.1007/s10557-018-6800-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
362 Zhang F, Sun W, Chen J, Jiang L, Yang P, Huang Y, Gong A, Liu S, Ma S. SREBP-2, a new target of metformin? Drug Des Devel Ther 2018;12:4163-70. [PMID: 30584280 DOI: 10.2147/DDDT.S190094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
363 Li T, Wan X, Ma J, Wu B. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Adv Ther 2018;35:2214-23. [PMID: 30390239 DOI: 10.1007/s12325-018-0823-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
364 Superko HR, Williams PT, Dansinger M, Schaefer E. Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines. Clin Cardiol 2019;42:101-10. [PMID: 30444024 DOI: 10.1002/clc.23115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
365 Cuschieri S, Vassallo J, Calleja N, Barbara C, Mamo J. The interaction of dyslipidaemia with glycaemia in an adult population study. J Diabetes Metab Disord 2018;17:315-23. [PMID: 30918867 DOI: 10.1007/s40200-018-0377-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
366 Wu NQ, Guo YL, Zhu CG, Gao Y, Zhao X, Sun D, Sun J, Xu RX, Liu G, Dong Q, Li JJ. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018;17:265. [PMID: 30470229 DOI: 10.1186/s12944-018-0909-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
367 Chooi YC, Ding C, Chan Z, Lo J, Choo J, Ding BTK, Leow MK, Magkos F. Lipoprotein Subclass Profile after Progressive Energy Deficits Induced by Calorie Restriction or Exercise. Nutrients 2018;10:E1814. [PMID: 30469333 DOI: 10.3390/nu10111814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
368 Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018;11:CD012502. [PMID: 30480766 DOI: 10.1002/14651858.CD012502.pub2] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
369 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143. [PMID: 30586774 DOI: 10.1161/cir.0000000000000625] [Cited by in Crossref: 250] [Cited by in F6Publishing: 606] [Article Influence: 62.5] [Reference Citation Analysis]
370 Shukla H, Mason JL, Sabyah A. Identifying genetic markers associated with susceptibility to cardiovascular diseases. Future Sci OA 2019;5:FSO350. [PMID: 30652019 DOI: 10.4155/fsoa-2018-0031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
371 Mackey RH. Low LDL-C and risk of hemorrhagic stroke in Chinese adults. J Clin Lipidol 2018;12:1111-2. [PMID: 30314803 DOI: 10.1016/j.jacl.2018.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
372 Jacob M, Holloway CJ. Cardiac Steatosis in HIV-A Marker or Mediator of Disease? Front Endocrinol (Lausanne) 2018;9:529. [PMID: 30364255 DOI: 10.3389/fendo.2018.00529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
373 Kim MH, Banerjee S, Zhao Y, Wang F, Zhang Y, Zhu Y, DeFerio J, Evans L, Park SM, Pathak J. Association networks in a matched case-control design - Co-occurrence patterns of preexisting chronic medical conditions in patients with major depression versus their matched controls. J Biomed Inform 2018;87:88-95. [PMID: 30300713 DOI: 10.1016/j.jbi.2018.09.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
374 Nayak A, Hayen A, Zhu L, McGeechan K, Glasziou P, Irwig L, Doust J, Gregory G, Bell K. Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis. BMJ Open 2018;8:e020584. [PMID: 30287603 DOI: 10.1136/bmjopen-2017-020584] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
375 Singh S, Zieman S, Go AS, Fortmann SP, Wenger NK, Fleg JL, Radziszewska B, Stone NJ, Zoungas S, Gurwitz JH. Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making. J Am Geriatr Soc 2018;66:2188-96. [PMID: 30277567 DOI: 10.1111/jgs.15449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
376 Kazemi M, McBreairty LE, Chizen DR, Pierson RA, Chilibeck PD, Zello GA. A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet in Combination with Exercise and Health Counselling on the Cardio-Metabolic Risk Profile in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients 2018;10:E1387. [PMID: 30274344 DOI: 10.3390/nu10101387] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
377 White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, Sattar N, Humphries SE, Hingorani AD, Holmes MV. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiol 2016;1:692-9. [PMID: 27487401 DOI: 10.1001/jamacardio.2016.1884] [Cited by in Crossref: 148] [Cited by in F6Publishing: 156] [Article Influence: 37.0] [Reference Citation Analysis]
378 Dizdarevic-Bostandzic A, Begovic E, Burekovic A, Velija-Asimi Z, Godinjak A, Karlovic V. Cardiovascular Risk Factors in Patients with Poorly Controlled Diabetes Mellitus. Med Arch 2018;72:13-6. [PMID: 29416211 DOI: 10.5455/medarh.2018.72.13-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
379 Francula-Zaninovic S, Nola IA. Management of Measurable Variable Cardiovascular Disease' Risk Factors. Curr Cardiol Rev 2018;14:153-63. [PMID: 29473518 DOI: 10.2174/1573403X14666180222102312] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
380 Li F, Liu G, Roudi R, Huang Q, Swierzy M, Ismail M, Zhao S, Rueckert JC. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. BMJ Open 2018;8:e022161. [PMID: 30206083 DOI: 10.1136/bmjopen-2018-022161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
381 Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR, Borén J. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab 2019;21:84-94. [PMID: 30073766 DOI: 10.1111/dom.13487] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
382 Jorge AM, Lu N, Keller SF, Rai SK, Zhang Y, Choi HK. The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases. J Rheumatol 2018;45:1689-95. [PMID: 30173155 DOI: 10.3899/jrheum.171389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
383 Feng Q, Wei WQ, Chung CP, Levinson RT, Sundermann AC, Mosley JD, Bastarache L, Ferguson JF, Cox NJ, Roden DM, Denny JC, Linton MF, Edwards DRV, Stein CM. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med 2018;15:e1002642. [PMID: 30153257 DOI: 10.1371/journal.pmed.1002642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
384 Yokoyama K, Tani S, Matsuo R, Matsumoto N. Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. Heart Vessels 2019;34:227-36. [PMID: 30140959 DOI: 10.1007/s00380-018-1247-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
385 Vincent J. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple. Clin Pharmacol Ther 2018;104:220-4. [DOI: 10.1002/cpt.1138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
386 Wolde HF, Atsedeweyen A, Jember A, Awoke T, Mequanent M, Tsegaye AT, Alemu S. Predictors of vascular complications among type 2 diabetes mellitus patients at University of Gondar Referral Hospital: a retrospective follow-up study. BMC Endocr Disord 2018;18:52. [PMID: 30064436 DOI: 10.1186/s12902-018-0280-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
387 Cabral CE, Klein MRST. Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases. Arq Bras Cardiol 2017;109:475-82. [PMID: 29267628 DOI: 10.5935/abc.20170158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
388 Asleh R, Briasoulis A, Pereira NL, Boilson BA, Edwards BS, Adigun R, Maltais S, Daly RC, Lerman A, Kushwaha SS. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC Heart Fail 2018;5:1118-29. [PMID: 30019530 DOI: 10.1002/ehf2.12329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
389 Virtanen M, Vahtera J, Singh-Manoux A, Elovainio M, Ferrie JE, Kivimäki M. Unfavorable and favorable changes in modifiable risk factors and incidence of coronary heart disease: The Whitehall II cohort study. Int J Cardiol 2018;269:7-12. [PMID: 30005835 DOI: 10.1016/j.ijcard.2018.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
390 Maki KC, Dicklin MR. Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut? Nutrients 2018;10:E864. [PMID: 29973554 DOI: 10.3390/nu10070864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
391 Wang Y, Ping Yen Yan B, Tomlinson B, Bruce Nichol M, Lee VWY. Clinical and Economic Analysis of Lipid Goal Attainments in Chinese Patients with Acute Coronary Syndrome Who Received Post-Percutaneous Coronary Intervention. J Atheroscler Thromb 2018;25:1255-73. [PMID: 29962381 DOI: 10.5551/jat.44818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
392 Fernandez DM, Clemente JC, Giannarelli C. Physical Activity, Immune System, and the Microbiome in Cardiovascular Disease. Front Physiol 2018;9:763. [PMID: 30013482 DOI: 10.3389/fphys.2018.00763] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
393 Astell-Burt T, Rowbotham S, Hawe P. Communicating the benefits of population health interventions: The health effects can be on par with those of medication. SSM Popul Health 2018;6:54-62. [PMID: 30202781 DOI: 10.1016/j.ssmph.2018.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
394 Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC, Sanghavi DM, Brown NC, Korenovska L, Huffman MD. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol. 2016;1:341-349. [PMID: 27438118 DOI: 10.1001/jamacardio.2016.0218] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
395 Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2018;6:CD012675. [PMID: 29932455 DOI: 10.1002/14651858.CD012675.pub2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
396 Dong QT, Gao Y, Wu NQ, Guo YL, Zhu CG, Li S, Liu HH, Cao YX, Zhang HW, Zhao X, Liu G, Dong Q, Li JJ. Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low-density lipoprotein cholesterol in diabetic patients with coronary artery disease. J Clin Lab Anal 2018;32:e22399. [PMID: 29380428 DOI: 10.1002/jcla.22399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
397 Agarwala A, Kulkarni S, Maddox T. The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Curr Cardiol Rep 2018;20:50. [PMID: 29779165 DOI: 10.1007/s11886-018-0995-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
398 Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc 2018;7:e008546. [PMID: 29739801 DOI: 10.1161/JAHA.118.008546] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
399 Hua Y, Xie M, Yin J, Wang Y, Gan L, Sang M, Sun X, Li M, Liu S, Xu J. Evaluation of effect of atorvastatin on left ventricular systolic function in rats with myocardial infarction via 2D-STI technique. Exp Ther Med 2018;15:4386-94. [PMID: 29725379 DOI: 10.3892/etm.2018.5951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
400 Yao X, Gersh BJ, Sangaralingham LR, Shah ND, Noseworthy PA. Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation. Am Heart J 2018;199:137-43. [PMID: 29754652 DOI: 10.1016/j.ahj.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
401 Alburikan KA, Asiri RM, Alhammad AM, Abuelizz AA, Bawazeer GA, Aljawadi MH. Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center. Ann Saudi Med 2017;37:276-81. [PMID: 28761026 DOI: 10.5144/0256-4947.2017.276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
402 Pinal-fernandez I, Casal-dominguez M, Mammen AL. Statins: pros and cons. Medicina Clínica (English Edition) 2018;150:398-402. [DOI: 10.1016/j.medcle.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
403 Gant CM, Binnenmars SH, Harmelink M, Soedamah-Muthu SS, Bakker SJL, Navis G, Laverman GD. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutr Diabetes 2018;8:24. [PMID: 29695715 DOI: 10.1038/s41387-018-0028-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
404 Dimmitt SB, Stampfer HG, Warren JB. The pharmacodynamic and clinical trial evidence for statin dose. Br J Clin Pharmacol 2018;84:1128-35. [PMID: 29393975 DOI: 10.1111/bcp.13539] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
405 DiNicolantonio JJ, McCarty MF. Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly? Open Heart 2018;5:e000789. [PMID: 29682295 DOI: 10.1136/openhrt-2018-000789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
406 Hua S, Ma C, Zhang J, Li J, Wu W, Xu N, Luo G, Zhao J. Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects. Front Pharmacol 2018;9:352. [PMID: 29695967 DOI: 10.3389/fphar.2018.00352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
407 Leng E, Xiao Y, Mo Z, Li Y, Zhang Y, Deng X, Zhou M, Zhou C, He Z, He J, Xiao L, Li J, Li W. Synergistic effect of phytochemicals on cholesterol metabolism and lipid accumulation in HepG2 cells. BMC Complement Altern Med 2018;18:122. [PMID: 29622007 DOI: 10.1186/s12906-018-2189-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
408 van Brunschot S, Hollemans RA, Bakker OJ, Besselink MG, Baron TH, Beger HG, Boermeester MA, Bollen TL, Bruno MJ, Carter R, French JJ, Coelho D, Dahl B, Dijkgraaf MG, Doctor N, Fagenholz PJ, Farkas G, Castillo CFD, Fockens P, Freeman ML, Gardner TB, Goor HV, Gooszen HG, Hannink G, Lochan R, McKay CJ, Neoptolemos JP, Oláh A, Parks RW, Peev MP, Raraty M, Rau B, Rösch T, Rovers M, Seifert H, Siriwardena AK, Horvath KD, van Santvoort HC. Minimally invasive and endoscopic versus open necrosectomy for necrotising pancreatitis: a pooled analysis of individual data for 1980 patients. Gut 2018;67:697-706. [PMID: 28774886 DOI: 10.1136/gutjnl-2016-313341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
409 Reklou A, Doumas M, Imprialos K, Stavropoulos K, Patoulias D, Athyros VG. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? Open Cardiovasc Med J 2018;12:29-40. [PMID: 29785212 DOI: 10.2174/1874192401812010029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
410 Muniyappa R, Noureldin RA, Abd-Elmoniem KZ, El Khouli RH, Matta JR, Hamimi A, Ranganath S, Hadigan C, Nieman LK, Gharib AM. Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. Cardiorenal Med 2018;8:140-50. [PMID: 29617001 DOI: 10.1159/000487205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
411 Liu Y, Song X, Zhou H, Zhou X, Xia Y, Dong X, Zhong W, Tang S, Wang L, Wen S, Xiao J, Tang L. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol 2018;9:530. [PMID: 29623075 DOI: 10.3389/fmicb.2018.00530] [Cited by in Crossref: 34] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
412 Ueda P, Lung TW, Lu Y, Salomon JA, Rahimi K, Clarke P, Danaei G. Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS One 2018;13:e0190688. [PMID: 29561843 DOI: 10.1371/journal.pone.0190688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
413 Asgari S, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, Khalili D. The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors. Sci Rep 2018;8:4928. [PMID: 29563602 DOI: 10.1038/s41598-018-23364-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
414 Clifton P, Keogh J. Cholesterol-Lowering Effects of Plant Sterols in One Serve of Wholegrain Wheat Breakfast Cereal Biscuits-a Randomised Crossover Clinical Trial. Foods 2018;7:E39. [PMID: 29547511 DOI: 10.3390/foods7030039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
415 Sundström J, Gulliksson G, Wirén M. Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis. BMJ Evid Based Med 2018;23:64-9. [PMID: 29595132 DOI: 10.1136/bmjebm-2017-110888] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
416 Gao S, Zhao D, Qi Y, Wang W, Wang M, Sun J, Liu J, Li Y, Liu J. Circulating Oxidized Low-Density Lipoprotein Levels Independently Predict 10-Year Progression of Subclinical Carotid Atherosclerosis: A Community-Based Cohort Study. J Atheroscler Thromb 2018;25:1032-43. [PMID: 29515051 DOI: 10.5551/jat.43299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
417 Van Cleemput JJA, Verbelen TOM, Van Aelst LNL, Rega FRL. How to obtain and maintain favorable results after heart transplantation: keys to success? Ann Cardiothorac Surg 2018;7:106-17. [PMID: 29492388 DOI: 10.21037/acs.2017.12.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
418 Weintraub WS, Lee KH. Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost. JACC Basic Transl Sci 2018;3:114-8. [PMID: 30062198 DOI: 10.1016/j.jacbts.2017.12.001] [Reference Citation Analysis]
419 Deljehier T, Pariente A, Miremont-Salamé G, Haramburu F, Nguyen L, Rubin S, Rigothier C, Théophile H. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2018;84:1057-63. [PMID: 29337401 DOI: 10.1111/bcp.13515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
420 Rueda-Gotor J, Genre F, Corrales A, Blanco R, Fuentevilla P, Portilla V, Expósito R, Arnaiz CM, Pina T, González-Juanatey C, Rodriguez-Rodriguez L, González-Gay MA. Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. Int J Rheumatol 2018;2018:1847894. [PMID: 29666651 DOI: 10.1155/2018/1847894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
421 Soulaidopoulos S, Nikiphorou E, Dimitroulas T, Kitas GD. The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis. Front Med (Lausanne) 2018;5:24. [PMID: 29473041 DOI: 10.3389/fmed.2018.00024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
422 Bonner C, Bell K, Jansen J, Glasziou P, Irwig L, Doust J, McCaffery K. Should heart age calculators be used alongside absolute cardiovascular disease risk assessment? BMC Cardiovasc Disord 2018;18:19. [PMID: 29409444 DOI: 10.1186/s12872-018-0760-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
423 Talbot D, Delaney JAC, Sandfort V, Herrington DM, McClelland RL. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf 2018;27:365-72. [PMID: 29405501 DOI: 10.1002/pds.4393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
424 Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP. Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease. Vasc Health Risk Manag 2018;14:23-36. [PMID: 29440909 DOI: 10.2147/VHRM.S146266] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
425 Garcia-Gil M, Comas-Cufí M, Blanch J, Martí R, Ponjoan A, Alves-Cabratosa L, Petersen I, Marrugat J, Elosua R, Grau M, Ramos R. Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study. Clin Pharmacol Ther 2018;104:719-32. [PMID: 29194590 DOI: 10.1002/cpt.954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
426 Lieb W, Enserro DM, Larson MG, Vasan RS. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart 2018;5:e000722. [PMID: 29387429 DOI: 10.1136/openhrt-2017-000722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
427 Hashi S, Sathiyakumar V, Byrne K, Elshazly MB, Jones SR, Martin SS. Statin Safety: What Every Health Care Provider Needs to Know. Curr Cardiovasc Risk Rep 2018;12. [DOI: 10.1007/s12170-018-0565-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
428 Parhofer KG. The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int 2016;113:261-8. [PMID: 27151464 DOI: 10.3238/arztebl.2016.0261] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
429 Borissov B, Urbich M, Georgieva B, Tsenov S, Villa G. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. J Mark Access Health Policy 2017;5:1412753. [PMID: 29321830 DOI: 10.1080/20016689.2017.1412753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Luymes CH, Poortvliet RKE, van Geloven N, de Waal MWM, Drewes YM, Blom JW, Smidt N, Assendelft WJJ, van den Hout WB, de Ruijter W, Numans ME. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Med 2018;16:5. [PMID: 29321031 DOI: 10.1186/s12916-017-0988-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
431 Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, Taylor B, Khan I, Manvelian G, White M, Jacobson TA. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther 2017;31:179-86. [PMID: 28421332 DOI: 10.1007/s10557-017-6723-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 11.8] [Reference Citation Analysis]
432 Knol RJJ, Kan H, Wondergem M, Cornel JH, Umans VAWM, van der Ploeg T, van der Zant FM. Exercise Electrocardiogram Neither Predicts Nor Excludes Coronary Artery Disease in Women with Low to Intermediate Risk. J Womens Health (Larchmt) 2018;27:476-84. [PMID: 29297745 DOI: 10.1089/jwh.2017.6433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
433 Vangen-Lønne AM, Ueda P, Gulayin P, Wilsgaard T, Mathiesen EB, Danaei G. Hypothetical interventions to prevent stroke: an application of the parametric g-formula to a healthy middle-aged population. Eur J Epidemiol 2018;33:557-66. [PMID: 29294206 DOI: 10.1007/s10654-017-0344-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
434 Song ZK, Cao HY, Wu HD, Zhou LT, Qin L. LPA Gene Polymorphisms and Gene Expression Associated with Coronary Artery Disease. Biomed Res Int 2017;2017:4138376. [PMID: 29457025 DOI: 10.1155/2017/4138376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
435 Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Med Clin (Barc) 2018;150:398-402. [PMID: 29292104 DOI: 10.1016/j.medcli.2017.11.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
436 Angelini S, Rosticci M, Massimo G, Musti M, Ravegnini G, Consolini N, Sammarini G, D'Addato S, Rizzoli E, Botbayev D, Borghi C, Cantelli-Forti G, Cicero AF, Hrelia P. Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. Int J Mol Sci 2017;19:E49. [PMID: 29295555 DOI: 10.3390/ijms19010049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
437 Soran H, Adam S, Mohammad JB, Ho JH, Schofield JD, Kwok S, Siahmansur T, Liu Y, Syed AA, Dhage SS, Stefanutti C, Donn R, Malik RA, Banach M, Durrington PN. Hypercholesterolaemia - practical information for non-specialists. Arch Med Sci 2018;14:1-21. [PMID: 29379528 DOI: 10.5114/aoms.2018.72238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
438 Sanin V, Pfetsch V, Koenig W. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Curr Cardiol Rep 2017;19:61. [PMID: 28528455 DOI: 10.1007/s11886-017-0869-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
439 Leibowitz M, Cohen-Stavi C, Basu S, Balicer RD. Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. Curr Cardiol Rep 2017;19:52. [PMID: 28432662 DOI: 10.1007/s11886-017-0858-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
440 Go AS, Fan D, Sung SH, Inveiss AI, Romo-LeTourneau V, Mallya UG, Boklage S, Lo JC. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. Am Heart J 2017;194:25-38. [PMID: 29223433 DOI: 10.1016/j.ahj.2017.08.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
441 Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017;31:2503-14. [PMID: 29112070 DOI: 10.1097/QAD.0000000000001675] [Cited by in Crossref: 44] [Cited by in F6Publishing: 19] [Article Influence: 8.8] [Reference Citation Analysis]
442 Kim Y, Keogh JB, Clifton PM. Benefits of Nut Consumption on Insulin Resistance and Cardiovascular Risk Factors: Multiple Potential Mechanisms of Actions. Nutrients 2017;9:E1271. [PMID: 29165404 DOI: 10.3390/nu9111271] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 12.6] [Reference Citation Analysis]
443 Chen K, Wu Q, Hu K, Yang C, Wu X, Cheung P, Williams KJ. Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1. Arterioscler Thromb Vasc Biol 2018;38:102-13. [PMID: 29162604 DOI: 10.1161/ATVBAHA.117.310358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
444 Weintraub WS, Boden WE. Making Cardiovascular Care More Responsive to Societal Needs. Am J Med 2017;130:1259-61. [PMID: 28797644 DOI: 10.1016/j.amjmed.2017.07.018] [Reference Citation Analysis]
445 Paim RTT, Benjamin SR, Rondina D, Marques MMM, Viana DA, Gonzaga MLDC, Vieira ÍGP, Mendes FNP, Rodrigues PAS, Guedes MIF. Antihypercholesterolemic Effects of Fruit Aqueous Extract of Copernicia prunifera (Miller) H. E. Moore in Mice Diet-Induced Hypercholesterolemia. Evid Based Complement Alternat Med 2017;2017:6376173. [PMID: 29081820 DOI: 10.1155/2017/6376173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
446 Schilling C, Knight J, Mortimer D, Petrie D, Clarke P, Chalmers J, Kerr A, Jackson R. Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy 2017;121:1233-9. [PMID: 29042060 DOI: 10.1016/j.healthpol.2017.09.022] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
447 Garshick M, Underberg JA. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep 2017;19:48. [PMID: 29038899 DOI: 10.1007/s11883-017-0685-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
448 Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW. Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 2017;27:101-11. [PMID: 28099408 DOI: 10.1097/FPC.0000000000000263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
449 Ganda OP, Mitri J. Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. Curr Cardiol Rep 2016;18:114. [PMID: 27747489 DOI: 10.1007/s11886-016-0790-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
450 Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;211:339-49. [PMID: 28982658 DOI: 10.1192/bjp.bp.117.200907] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
451 Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS. Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. Arq Bras Cardiol 2017;108:508-17. [PMID: 28699974 DOI: 10.5935/abc.20170088] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
452 Van't Hof JR, Duval S, Walts A, Kopecky SL, Luepker RV, Hirsch AT. Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007-2015: A Serial, Cross-sectional Study. J Am Heart Assoc 2017;6:e006328. [PMID: 28974502 DOI: 10.1161/JAHA.117.006328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
453 Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. J Am Heart Assoc 2017;6:e005367. [PMID: 28971955 DOI: 10.1161/JAHA.116.005367] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
454 Tani S, Nagao K, Kawauchi K, Yagi T, Atsumi W, Matsuo R, Hirayama A. The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. Am J Cardiovasc Drugs 2017;17:409-20. [PMID: 28634822 DOI: 10.1007/s40256-017-0238-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
455 Packard CJ, Young R, Ross K, Ford I, Ambegaonkar BM, Brudi P, McCowan C. Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. Eur Heart J Qual Care Clin Outcomes 2017;3:281-8. [PMID: 29044395 DOI: 10.1093/ehjqcco/qcx012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
456 Kjølbæk L, Lorenzen JK, Larsen LH, Astrup A. Calcium intake and the associations with faecal fat and energy excretion, and lipid profile in a free-living population. J Nutr Sci 2017;6:e50. [PMID: 29152254 DOI: 10.1017/jns.2017.55] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
457 Urbano F, Bugliani M, Filippello A, Scamporrino A, Di Mauro S, Di Pino A, Scicali R, Noto D, Rabuazzo AM, Averna M, Marchetti P, Purrello F, Piro S. Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress. Sci Rep 2017;7:11863. [PMID: 28928397 DOI: 10.1038/s41598-017-11070-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
458 Berent R, Berent T, Sinzinger H. Therapieoptionen von Fettstoffwechselstörungen. Wien Med Wochenschr 2018;168:7-15. [DOI: 10.1007/s10354-017-0594-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
459 Bușilă C, Stuparu-crețu M, Barna O, Balan G. Dyslipidemia in children as a risk factor for cardiovascular diseases. Biotechnology & Biotechnological Equipment 2017;31:1192-7. [DOI: 10.1080/13102818.2017.1376596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
460 Xu L, Borges MC, Hemani G, Lawlor DA. The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. Diabetologia 2017;60:2210-20. [PMID: 28889241 DOI: 10.1007/s00125-017-4396-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
461 Huber D, Henriksson R, Jakobsson S, Mooe T. Nurse-led telephone-based follow-up of secondary prevention after acute coronary syndrome: One-year results from the randomized controlled NAILED-ACS trial. PLoS One 2017;12:e0183963. [PMID: 28886083 DOI: 10.1371/journal.pone.0183963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
462 Adham S, Miranda S, Doucet J, Lévesque H, Benhamou Y. [Statins in primary prevention of cardiovascular disease]. Rev Med Interne 2018;39:42-9. [PMID: 28866432 DOI: 10.1016/j.revmed.2017.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
463 Anyanwagu U, Mamza J, Donnelly R, Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovasc Diabetol 2017;16:107. [PMID: 28830436 DOI: 10.1186/s12933-017-0587-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
464 Chisnell J, Marshall T, Hyde C, Zhelev Z, Fleming LE. A content analysis of the representation of statins in the British newsprint media. BMJ Open 2017;7:e012613. [PMID: 28827228 DOI: 10.1136/bmjopen-2016-012613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
465 Journath G, Hambraeus K, Hagström E, Pettersson B, Löthgren M. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline. BMC Cardiovasc Disord 2017;17:224. [PMID: 28814290 DOI: 10.1186/s12872-017-0659-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
466 Tomasik T, Krzysztoń J, Dubas-Jakóbczyk K, Kijowska V, Windak A. The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review. Acta Cardiol 2017;72:370-9. [PMID: 28705107 DOI: 10.1080/00015385.2017.1335052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
467 Ueda P, Lung TW, Clarke P, Danaei G. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis. Br J Gen Pract 2017;67:e598-608. [PMID: 28760741 DOI: 10.3399/bjgp17X692141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
468 Parkin L, Sharples KJ, Barson DJ, Blank ML. Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PLoS One 2017;12:e0182066. [PMID: 28753656 DOI: 10.1371/journal.pone.0182066] [Reference Citation Analysis]
469 Abdullah MMH, Marinangeli CPF, Jones PJH, Carlberg JG. Canadian Potential Healthcare and Societal Cost Savings from Consumption of Pulses: A Cost-Of-Illness Analysis. Nutrients 2017;9:E793. [PMID: 28737688 DOI: 10.3390/nu9070793] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
470 Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr 2017;9:53. [PMID: 28725272 DOI: 10.1186/s13098-017-0251-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
471 Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA 2017;318:156-66. [PMID: 28697252 DOI: 10.1001/jama.2017.7967] [Cited by in Crossref: 213] [Cited by in F6Publishing: 186] [Article Influence: 42.6] [Reference Citation Analysis]
472 Dixon DL, Buckley LF, Trankle CR, Kadariya D, Abbate A. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Des Devel Ther 2017;11:2121-9. [PMID: 28744103 DOI: 10.2147/DDDT.S114091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
473 Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation 2017;136:1087-98. [PMID: 28687710 DOI: 10.1161/CIRCULATIONAHA.117.027067] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 10.4] [Reference Citation Analysis]
474 Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis 2017;16:132. [PMID: 28679436 DOI: 10.1186/s12944-017-0515-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 121] [Article Influence: 20.8] [Reference Citation Analysis]
475 Srikanth S, Deedwania P. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Curr Hypertens Rep 2016;18:76. [PMID: 27730495 DOI: 10.1007/s11906-016-0683-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
476 Kameda A, Nakamura A, Kondo Y, Kimura M, Terauchi Y. Effects of switching to low-dose rosuvastatin (5 mg/day) on glucose metabolism and lipid profiles in Japanese patients with type 2 diabetes and dyslipidemia: a single-arm, prospective, interventional trial. Diabetol Int 2017;8:383-91. [PMID: 30603344 DOI: 10.1007/s13340-017-0328-9] [Reference Citation Analysis]
477 Fung CSC, Wan EYF, Chan AKC, Lam CLK. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord 2017;17:166. [PMID: 28645252 DOI: 10.1186/s12872-017-0599-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
478 Suzumura EA, Ribeiro RA, Kawano-Dourado L, de Barros E Silva PG, Oliveira C, Figueiró MF, Cavalcanti AB, Lopes RD, Berwanger O. Effects of perioperative statin use on cardiovascular complications in patients submitted to non-cardiac surgery: protocol for a systematic review, meta-analysis, and trial sequential analysis. Syst Rev 2017;6:116. [PMID: 28629445 DOI: 10.1186/s13643-017-0500-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
479 Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017;174:3898-913. [PMID: 28409825 DOI: 10.1111/bph.13818] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 18.0] [Reference Citation Analysis]
480 Herttua K, Martikainen P, Batty GD, Kivimäki M. Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke. J Am Coll Cardiol 2016;67:1507-15. [PMID: 27150680 DOI: 10.1016/j.jacc.2016.01.044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
481 Ferreira AM, Marques da Silva P. Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. Am J Cardiovasc Drugs 2017;17:169-81. [PMID: 27943172 DOI: 10.1007/s40256-016-0205-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
482 Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 2017;14:577-90. [PMID: 28569269 DOI: 10.1038/nrcardio.2017.78] [Cited by in Crossref: 227] [Cited by in F6Publishing: 230] [Article Influence: 45.4] [Reference Citation Analysis]
483 Phrommintikul A, Krittayaphong R, Wongcharoen W, Yamwong S, Boonyaratavej S, Kunjara-Na-Ayudhya R, Tatsanavivat P, Sritara P; CORE-Thailand Investigators. Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study. Singapore Med J 2017;58:535-42. [PMID: 28540395 DOI: 10.11622/smedj.2017044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
484 Kim DS, Jackson AU, Li YK, Stringham HM, Kuusisto J, Kangas AJ, Soininen P, Ala-Korpela M, Burant CF, Salomaa V, Boehnke M, Laakso M, Speliotes EK. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns. J Lipid Res 2017;58:1471-81. [PMID: 28539357 DOI: 10.1194/jlr.P076034] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
485 Feinstein MJ, Lloyd-Jones DM. Monoclonal Antibodies for Lipid Management. Curr Atheroscler Rep 2016;18:39. [PMID: 27221501 DOI: 10.1007/s11883-016-0593-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
486 Xue Y, Tao L, Wu S, Wang G, Qian L, Li J, Liao L, Tang J, Ji K. Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial. BMC Cardiovasc Disord 2017;17:127. [PMID: 28521773 DOI: 10.1186/s12872-017-0560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
487 Patel KK, Taksler GB, Hu B, Rothberg MB. Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys. Ann Intern Med 2017;166:876-82. [PMID: 28505660 DOI: 10.7326/M16-2052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
488 Sarasua SM, Li J, Hernandez GT, Ferdinand KC, Tobin JN, Fiscella KA, Jones DW, Sinopoli A, Egan BM. Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy. J Clin Hypertens (Greenwich) 2017;19:850-60. [PMID: 28480530 DOI: 10.1111/jch.13004] [Reference Citation Analysis]
489 Pandya A, Sy S, Cho S, Alam S, Weinstein MC, Gaziano TA. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making 2017;37:802-14. [PMID: 28490271 DOI: 10.1177/0272989X17706081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
490 Eckard AR, Meissner EG, Singh I, McComsey GA. Cardiovascular Disease, Statins, and HIV. J Infect Dis 2016;214 Suppl 2:S83-92. [PMID: 27625435 DOI: 10.1093/infdis/jiw288] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
491 Reith C, Staplin N, Herrington WG, Stevens W, Emberson J, Haynes R, Mafham M, Armitage J, Cass A, Craig JC, Jiang L, Pedersen T, Baigent C, Landray MJ; SHARP Collaborative Group. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. BMC Nephrol 2017;18:147. [PMID: 28460629 DOI: 10.1186/s12882-017-0545-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
492 Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748. [PMID: 28453187 DOI: 10.1002/14651858.cd011748.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
493 Lauer MS, Gordon D, Wei G, Pearson G. Efficient design of clinical trials and epidemiological research: is it possible? Nat Rev Cardiol 2017;14:493-501. [PMID: 28447664 DOI: 10.1038/nrcardio.2017.60] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
494 Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ 2017;357:j1648. [PMID: 28438747 DOI: 10.1136/bmj.j1648] [Cited by in Crossref: 78] [Cited by in F6Publishing: 88] [Article Influence: 15.6] [Reference Citation Analysis]
495 Chen YW, Li CH, Yang CD, Liu CH, Chen CH, Sheu JJ, Lin SK, Chen AC, Chen PK, Chen PL, Yeh CH, Chen JR, Hsiao YJ, Lin CH, Hsu SP, Chen TS, Sung SF, Yu SC, Muo CH, Wen CP, Sung FC, Jeng JS, Hsu CY; Taiwan Stroke Registry Investigators. Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. PLoS One 2017;12:e0171379. [PMID: 28422955 DOI: 10.1371/journal.pone.0171379] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
496 Bergt S, Grub A, Wagner S, Engelke H, Nöldge-Schomburg G, Vollmar B, Roesner JP, Wagner NM. Pravastatin But Not Simvastatin Improves Survival and Neurofunctional Outcome After Cardiac Arrest and Cardiopulmonary Resuscitation. JACC Basic Transl Sci 2017;2:149-59. [PMID: 30167563 DOI: 10.1016/j.jacbts.2017.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
497 Fonseca FA, Izar MC. High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. Clinics (Sao Paulo) 2016;71:235-42. [PMID: 27166776 DOI: 10.6061/clinics/2016(04)11] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
498 Latimer J, Batty JA, Neely RD, Kunadian V. PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis 2016;42:405-19. [PMID: 27095708 DOI: 10.1007/s11239-016-1364-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
499 Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther 2017;7:S4-S10. [PMID: 28529917 DOI: 10.21037/cdt.2017.04.04] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
500 Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs 2016;76:1175-90. [PMID: 27456066 DOI: 10.1007/s40265-016-0613-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
501 Collins DR, Tompson AC, Onakpoya IJ, Roberts N, Ward AM, Heneghan CJ. Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open 2017;7:e013650. [PMID: 28341688 DOI: 10.1136/bmjopen-2016-013650] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
502 Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887. [PMID: 28290160 DOI: 10.1002/14651858.CD006887.pub4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
503 Balder JW, de Vries JK, Mulder DJ, Kamphuisen PW. Time to improve statin prescription guidelines in low-risk patients? Eur J Prev Cardiol 2017;24:1064-70. [PMID: 28429651 DOI: 10.1177/2047487317698585] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
504 Amor AJ, Serra-Mir M, Martínez-González MA, Corella D, Salas-Salvadó J, Fitó M, Estruch R, Serra-Majem L, Arós F, Babio N, Ros E, Ortega E; PREDIMED Investigators . Prediction of Cardiovascular Disease by the Framingham-REGICOR Equation in the High-Risk PREDIMED Cohort: Impact of the Mediterranean Diet Across Different Risk Strata. J Am Heart Assoc 2017;6:e004803. [PMID: 28288977 DOI: 10.1161/JAHA.116.004803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
505 Chen W, Huang Z, Bi M, Xu X, Zhao N. Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials. Lipids Health Dis 2017;16:53. [PMID: 28288631 DOI: 10.1186/s12944-017-0439-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
506 Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 2017;18:331-44. [PMID: 28286336 DOI: 10.1038/nrg.2016.160] [Cited by in Crossref: 236] [Cited by in F6Publishing: 236] [Article Influence: 47.2] [Reference Citation Analysis]
507 Wierzbicki AS, Grant P. Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. Clin Med (Lond) 2016;16:353-7. [PMID: 27481380 DOI: 10.7861/clinmedicine.16-4-353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
508 Weintraub WS, Gidding SS. PCSK9 Inhibitors: A Technology Worth Paying For? Pharmacoeconomics 2016;34:217-20. [PMID: 26689785 DOI: 10.1007/s40273-015-0355-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
509 Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017;3:CD009868. [PMID: 28263370 DOI: 10.1002/14651858.CD009868.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
510 Tada H, Kawashiri MA, Yamagishi M. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. J Atheroscler Thromb 2017;24:452-61. [PMID: 28250266 DOI: 10.5551/jat.RV17002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
511 Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation 2017;135:2091-101. [PMID: 28223407 DOI: 10.1161/CIRCULATIONAHA.116.024436] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 46.6] [Reference Citation Analysis]
512 Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 2017;7:e013255. [PMID: 28213597 DOI: 10.1136/bmjopen-2016-013255] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
513 Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment. Neth Heart J 2017;25:231-42. [PMID: 28194698 DOI: 10.1007/s12471-017-0959-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 15.6] [Reference Citation Analysis]
514 Sigala F, Efentakis P, Karageorgiadi D, Filis K, Zampas P, Iliodromitis EK, Zografos G, Papapetropoulos A, Andreadou I. Reciprocal regulation of eNOS, H2S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin. Redox Biol 2017;12:70-81. [PMID: 28214453 DOI: 10.1016/j.redox.2017.02.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
515 Pletcher MJ, Pignone M, Jarmul JA, Moran AE, Vittinghoff E, Newman T. Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. J Am Heart Assoc 2017;6:e004316. [PMID: 28188251 DOI: 10.1161/JAHA.116.004316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
516 Chang YH, Hwu DW, Kao WP, Lee YJ. Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3. Rev Diabet Stud 2016;13:212-4. [PMID: 28278306 DOI: 10.1900/RDS.2016.13.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
517 Hung MS, Chen IC, Lee CP, Huang RJ, Chen PC, Tsai YH, Yang YH. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017;12:e0171137. [PMID: 28158206 DOI: 10.1371/journal.pone.0171137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 45] [Article Influence: 6.2] [Reference Citation Analysis]
518 Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med 2017;15:22. [PMID: 28153024 DOI: 10.1186/s12916-017-0787-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
519 Tani S, Nagao K, Yagi T, Atsumi W, Hirayama A. Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study. Am J Cardiovasc Drugs 2017;17:49-59. [PMID: 27778191 DOI: 10.1007/s40256-016-0195-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
520 Berwanger O, de Barros E Silva PG, Barbosa RR, Precoma DB, Figueiredo EL, Hajjar LA, Kruel CD, Alboim C, Almeida AP, Dracoulakis MD, Filho HV, Carmona MJ, Maia LN, de Oliveira Filho JB, Saraiva JF, Soares RM, Damiani L, Paisani D, Kodama AA, Gonzales B, Ikeoka DT, Devereaux PJ, Lopes RD; LOAD Investigators. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. Am Heart J 2017;184:88-96. [PMID: 27892891 DOI: 10.1016/j.ahj.2016.11.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
521 González-juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL, Baron-esquivias G, Galve E, Lidón RM, Garcia-moll FX, Sánchez PL, Suárez C, Millán J, Pallares V, Alemán JJ, Egocheaga I. Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular. Medicina Clínica 2017;148:139.e1-139.e15. [DOI: 10.1016/j.medcli.2016.10.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
522 Gulayin P, Irazola V, Lozada A, Chaparro M, Santero M, Gutierrez L, Poggio R, Beratarrechea A, Rubinstein A. Educational intervention to improve effectiveness in treatment and control of patients with high cardiovascular risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial. BMJ Open 2017;7:e014420. [PMID: 28143840 DOI: 10.1136/bmjopen-2016-014420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
523 Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol 2017;106:237-48. [PMID: 28124099 DOI: 10.1007/s00392-016-1069-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
524 Yang Q, Zhong Y, Gillespie C, Merritt R, Bowman B, George MG, Flanders WD. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study. BMJ Open 2017;7:e011684. [PMID: 28119384 DOI: 10.1136/bmjopen-2016-011684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
525 Karmali KN, Lloyd-Jones DM. Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention. Hypertension 2017;69:e2-9. [PMID: 28115516 DOI: 10.1161/HYPERTENSIONAHA.116.08249] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
526 Gaziano T, Cho S, Sy S, Pandya A, Levitt NS, Steyn K. Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa. Health Aff (Millwood) 2015;34:1578-85. [PMID: 26355061 DOI: 10.1377/hlthaff.2015.0351] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
527 Foody JM, Toth PP, Tershakovec AM, Musliner T, Tomassini JE, Lowe RS, Neff DR, Davis HR. Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology 2014;9:441-70. [DOI: 10.2217/clp.14.36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
528 Fernandez ML, Andersen CJ. Effects of dietary cholesterol in diabetes and cardiovascular disease. Clinical Lipidology 2014;9:607-16. [DOI: 10.2217/clp.14.40] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
529 Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med 2017;13:810-4. [PMID: 28450903 DOI: 10.3892/etm.2017.4055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
530 Zhan S, Xia P, Tang M, Liu F, Shu M, Wu X; Cochrane Heart Group. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012502] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
531 Toplak H, Ludvik B, Lechleitner M, Dieplinger H, Föger B, Paulweber B, Weber T, Watschinger B, Horn S, Wascher TC, Drexel H, Brodmann M, Pilger E, Rosenkranz A, Pohanka E, Oberbauer R, Traindl O, Roithinger FX, Metzler B, Haring HP, Kiechl S. Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. Wien Klin Wochenschr 2016;128 Suppl 2:S216-28. [PMID: 27052248 DOI: 10.1007/s00508-016-0993-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
532 Arrigoni E, Del Re M, Fidilio L, Fogli S, Danesi R, Di Paolo A. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. Int J Mol Sci. 2017;18. [PMID: 28067828 DOI: 10.3390/ijms18010104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
533 Homer K, Boomla K, Hull S, Dostal I, Mathur R, Robson J. Statin prescribing for primary prevention of cardiovascular disease: a cross-sectional, observational study. Br J Gen Pract 2015;65:e538-44. [PMID: 26212850 DOI: 10.3399/bjgp15X686113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
534 Labrador Gómez PJ, González Sanchidrián S, Fuentes Rodríguez JM, Gómez-Martino Arroyo JR. [Trend of lipid profile in general population from Caceres Health Area]. Hipertens Riesgo Vasc 2017;34:17-23. [PMID: 27650945 DOI: 10.1016/j.hipert.2016.07.003] [Reference Citation Analysis]
535 Yerrakalva D, Griffin SJ. Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon? Br J Gen Pract 2017;67:40-1. [PMID: 28034950 DOI: 10.3399/bjgp17X688789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
536 Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract 2016;2016:e201635. [PMID: 28979904 DOI: 10.21542/gcsp.2016.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
537 Steen DL, Khan I, Becker L, Foody JM, Gorcyca K, Sanchez RJ, Giugliano RP. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. Clin Cardiol 2017;40:155-62. [PMID: 28026031 DOI: 10.1002/clc.22641] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
538 Hasani-Ranjbar S, Ejtahed HS. Statins alone or polypill for primary prevention of cardiovascular diseases. J Diabetes Metab Disord 2016;15:55. [PMID: 27981041 DOI: 10.1186/s40200-016-0280-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
539 Tabas I. 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol 2017;37:183-9. [PMID: 27979856 DOI: 10.1161/ATVBAHA.116.308036] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
540 Swerdlow DI. Mendelian Randomization and Type 2 Diabetes. Cardiovasc Drugs Ther 2016;30:51-7. [PMID: 26809778 DOI: 10.1007/s10557-016-6638-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
541 Nayor M, Vasan RS. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines. Circulation 2016;133:1795-806. [PMID: 27143546 DOI: 10.1161/CIRCULATIONAHA.116.021407] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
542 Mansi IA. Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data. Am J Cardiovasc Drugs 2016;16:407-18. [PMID: 27677504 DOI: 10.1007/s40256-016-0190-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
543 Singh RS, Chaudhary DK, Mohan A, Kumar P, Chaturvedi CP, Ecelbarger CM, Godbole MM, Tiwari S. Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor. Sci Rep 2016;6:38034. [PMID: 27901066 DOI: 10.1038/srep38034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
544 Herrington WG, Emberson J, Mihaylova B, Collins R, Baigent C; Cholesterol Treatment Trialists' Collaboration. Are statins useful in patients with advanced chronic kidney disease? - Authors' reply. Lancet Diabetes Endocrinol 2016;4:971-2. [PMID: 27886746 DOI: 10.1016/S2213-8587(16)30266-2] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
545 Chen L, Ishigami T. Intestinal Microbiome and Atherosclerosis - Authors' Reply. EBioMedicine 2016;13:19-20. [PMID: 27856193 DOI: 10.1016/j.ebiom.2016.10.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
546 Konfino J, Fernandez A, Penko J, Mason A, Martinez E, Coxson P, Heller D, Moran A, Bibbins-Domingo K, Pérez-Stable EJ, Mejía R. Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina. J Gen Intern Med 2017;32:524-33. [PMID: 27853916 DOI: 10.1007/s11606-016-3907-8] [Reference Citation Analysis]
547 Gitsels LA, Kulinskaya E, Steel N. Survival Benefits of Statins for Primary Prevention: A Cohort Study. PLoS One 2016;11:e0166847. [PMID: 27861639 DOI: 10.1371/journal.pone.0166847] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
548 Finnikin S, Ryan R, Marshall T. Cohort study investigating the relationship between cholesterol, cardiovascular risk score and the prescribing of statins in UK primary care: study protocol. BMJ Open 2016;6:e013120. [PMID: 27856481 DOI: 10.1136/bmjopen-2016-013120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
549 Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, Gillman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre ML, Mangione CM, Phillips WR, Owens DK, Phipps MG, Pignone MP; US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016;316:1997-2007. [PMID: 27838723 DOI: 10.1001/jama.2016.15450] [Cited by in Crossref: 329] [Cited by in F6Publishing: 333] [Article Influence: 54.8] [Reference Citation Analysis]
550 Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016;316:2008-24. [PMID: 27838722 DOI: 10.1001/jama.2015.15629] [Cited by in Crossref: 322] [Cited by in F6Publishing: 295] [Article Influence: 53.7] [Reference Citation Analysis]
551 Gaudette É, Goldman DP, Messali A, Sood N. Do Statins Reduce the Health and Health Care Costs of Obesity? Pharmacoeconomics 2015;33:723-34. [PMID: 25576147 DOI: 10.1007/s40273-014-0234-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
552 Crossan C, Lord J, Ryan R, Nherera L, Marshall T. Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study. Br J Gen Pract 2017;67:e67-77. [PMID: 27821671 DOI: 10.3399/bjgp16X687973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
553 Chia YC, Lim HM, Ching SM. Long-Term Visit-to-Visit Blood Pressure Variability and Renal Function Decline in Patients With Hypertension Over 15 Years. J Am Heart Assoc 2016;5:e003825. [PMID: 27821404 DOI: 10.1161/JAHA.116.003825] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
554 Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2017;69:1617-1636. [PMID: 27825770 DOI: 10.1016/j.jacc.2016.10.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
555 Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. Circulation 2017;135:e793-813. [PMID: 27815375 DOI: 10.1161/CIR.0000000000000467] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
556 Dzeshka MS, Gill PS, Lip GY. Cardiovascular risk prediction: balancing complexity against simple practicality. Br J Gen Pract 2015;65:4-5. [PMID: 25548292 DOI: 10.3399/bjgp15X683005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
557 Kohli P, Knowles JW, Sarraju A, Waters DD, Reaven G. Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). Am J Cardiol 2016;118:1275-81. [PMID: 27614854 DOI: 10.1016/j.amjcard.2016.07.054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
558 Weitgasser R, Ratzinger M, Hemetsberger M, Siostrzonek P. [LDL-cholesterol and cardiovascular events: the lower the better?]. Wien Med Wochenschr 2018;168:108-20. [PMID: 27770320 DOI: 10.1007/s10354-016-0518-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
559 Walton GM, Stockley JA, Griffiths D, Sadhra CS, Purvis T, Sapey E. Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? J Clin Med 2016;5:E89. [PMID: 27727158 DOI: 10.3390/jcm5100089] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
560 Schumacher TL, Burrows TL, Rollo ME, Spratt NJ, Callister R, Collins CE. Effectiveness of a Brief Dietetic Intervention for Hyperlipidaemic Adults Using Individually-Tailored Dietary Feedback. Healthcare (Basel) 2016;4:E75. [PMID: 27727165 DOI: 10.3390/healthcare4040075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
561 März W, Scharnagl H, Gouni-Berthold I, Silbernagel G, Dressel A, Grammer TB, Landmesser U, Dieplinger H, Windler E, Laufs U. LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. Am J Cardiovasc Drugs 2016;16:323-36. [PMID: 27430233 DOI: 10.1007/s40256-016-0179-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
562 Hassan Y, Ford J, Steel N, Sheldon J, Fleetcroft R. Why are statin prescribing guidelines for primary prevention not always followed in primary care? Br J Gen Pract 2016;66:536-7. [PMID: 27688515 DOI: 10.3399/bjgp16X687481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
563 Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis 2016;29:1-9. [PMID: 26658651 DOI: 10.1097/QCO.0000000000000223] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
564 Yılmaz M, Atar İ, Hasırcı S, Akyol K, Tekin A, Karaçağlar E, Çiftçi O, Müderrisoğlu H. Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort. Anatol J Cardiol 2017;17:92-6. [PMID: 27684519 DOI: 10.14744/AnatolJCardiol.2016.6965] [Reference Citation Analysis]
565 Yeramaneni S, Kleindorfer DO, Sucharew H, Alwell K, Moomaw CJ, Flaherty ML, Woo D, Adeoye O, Ferioli S, de Los Rios La Rosa F, Martini S, Mackey J, Khatri P, Kissela BM, Khoury JC. Hyperlipidemia is associated with lower risk of poststroke mortality independent of statin use: A population-based study. Int J Stroke 2017;12:152-60. [PMID: 27649737 DOI: 10.1177/1747493016670175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
566 Smit RA, Postmus I, Trompet S, Barnes MR, Warren H, Arsenault BJ, Chasman DI, Cupples LA, Hitman GA, Krauss RM, Li X, Psaty BM, Stein CM, Rotter JI, Jukema JW. Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. Pharmacogenomics 2016;17:1621-8. [PMID: 27648687 DOI: 10.2217/pgs-2016-0091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
567 Burton BK, Deegan PB, Enns GM, Guardamagna O, Horslen S, Hovingh GK, Lobritto SJ, Malinova V, McLin VA, Raiman J, Di Rocco M, Santra S, Sharma R, Sykut-Cegielska J, Whitley CB, Eckert S, Valayannopoulos V, Quinn AG. Clinical Features of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2015;61:619-25. [PMID: 26252914 DOI: 10.1097/MPG.0000000000000935] [Cited by in Crossref: 60] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
568 Giner-Galvañ V, Esteban-Giner MJ, Pallarés-Carratalá V. Overview of guidelines for the management of dyslipidemia: EU perspectives. Vasc Health Risk Manag 2016;12:357-69. [PMID: 27660458 DOI: 10.2147/VHRM.S89038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
569 Fiuzat M, Stockbridge N, Califf RM. Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead. JACC Basic Transl Sci 2016;1:309-12. [PMID: 30167521 DOI: 10.1016/j.jacbts.2016.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
570 Egan BM, Li J, White K, Fleming DO, Connell K, Hernandez GT, Jones DW, Ferdinand KC, Sinopoli A. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. J Am Heart Assoc 2016;5:e003558. [PMID: 27543306 DOI: 10.1161/JAHA.116.003558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
571 Cho YK, Jung CH, Kang YM, Hwang JY, Kim EH, Yang DH, Kang JW, Park JY, Kim HK, Lee WJ. 2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population. J Am Heart Assoc 2016;5:e003410. [PMID: 27543305 DOI: 10.1161/JAHA.116.003410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
572 Chen GC, Wang Y, Tong X, Szeto IMY, Smit G, Li ZN, Qin LQ. Cheese consumption and risk of cardiovascular disease: a meta-analysis of prospective studies. Eur J Nutr 2017;56:2565-75. [PMID: 27517544 DOI: 10.1007/s00394-016-1292-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
573 Nilsson G, Samuelsson E, Söderström L, Mooe T. Low use of statins for secondary prevention in primary care: a survey in a northern Swedish population. BMC Fam Pract 2016;17:110. [PMID: 27515746 DOI: 10.1186/s12875-016-0505-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
574 Chen GC, Wan ZX, Qin LQ. Nut consumption, lipid profile, and health outcomes. Am J Clin Nutr 2016;103:1185-6. [PMID: 27037363 DOI: 10.3945/ajcn.115.128272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
575 Würtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, Tiainen M, Perola M, Tillin T, Hughes AD, Mäntyselkä P, Kähönen M, Lehtimäki T, Sattar N, Hingorani AD, Casas JP, Salomaa V, Kivimäki M, Järvelin MR, Davey Smith G, Vanhala M, Lawlor DA, Raitakari OT, Chaturvedi N, Kettunen J, Ala-Korpela M. Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J Am Coll Cardiol 2016;67:1200-10. [PMID: 26965542 DOI: 10.1016/j.jacc.2015.12.060] [Cited by in Crossref: 114] [Cited by in F6Publishing: 88] [Article Influence: 19.0] [Reference Citation Analysis]
576 Skilving I, Eriksson M, Rane A, Ovesjö ML. Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences. Eur J Clin Pharmacol 2016;72:1171-6. [PMID: 27484241 DOI: 10.1007/s00228-016-2105-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
577 Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif JC; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. Am Heart J 2016;178:135-44. [PMID: 27502861 DOI: 10.1016/j.ahj.2016.05.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
578 Yamamoto T, Wada F, Harada-Shiba M. Development of Antisense Drugs for Dyslipidemia. J Atheroscler Thromb 2016;23:1011-25. [PMID: 27466159 DOI: 10.5551/jat.RV16001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
579 Dandapat S, Robinson JG. Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Curr Neurol Neurosci Rep. 2016;16:24. [PMID: 26838351 DOI: 10.1007/s11910-016-0621-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
580 Higuita-Castro N, Shukla VC, Mihai C, Ghadiali SN. Simvastatin Treatment Modulates Mechanically-Induced Injury and Inflammation in Respiratory Epithelial Cells. Ann Biomed Eng 2016;44:3632-44. [PMID: 27411707 DOI: 10.1007/s10439-016-1693-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
581 Ashauer R, Albert C, Augustine S, Cedergreen N, Charles S, Ducrot V, Focks A, Gabsi F, Gergs A, Goussen B, Jager T, Kramer NI, Nyman AM, Poulsen V, Reichenberger S, Schäfer RB, Van den Brink PJ, Veltman K, Vogel S, Zimmer EI, Preuss TG. Modelling survival: exposure pattern, species sensitivity and uncertainty. Sci Rep 2016;6:29178. [PMID: 27381500 DOI: 10.1038/srep29178] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
582 Singh AK, Singh R. Triglyceride and cardiovascular risk: A critical appraisal. Indian J Endocrinol Metab 2016;20:418-28. [PMID: 27366705 DOI: 10.4103/2230-8210.183460] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
583 Heymann AD, Ravona-Springer R, Moshier EL, Godbold J, Beeri MS. Statin Use is Associated with Better Cognitive Function in Elderly with Type 2 Diabetes. J Alzheimers Dis 2015;47:55-9. [PMID: 26402754 DOI: 10.3233/JAD-142571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
584 Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ 2016;353:i3305. [PMID: 27353261 DOI: 10.1136/bmj.i3305] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
585 Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ 2016;353:i3283. [PMID: 27353418 DOI: 10.1136/bmj.i3283] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 18.7] [Reference Citation Analysis]
586 Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Res 2016;5:F1000 Faculty Rev-1499. [PMID: 27408693 DOI: 10.12688/f1000research.8629.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
587 Albert C, Vogel S, Ashauer R. Computationally Efficient Implementation of a Novel Algorithm for the General Unified Threshold Model of Survival (GUTS). PLoS Comput Biol 2016;12:e1004978. [PMID: 27340823 DOI: 10.1371/journal.pcbi.1004978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
588 Bhatt A, Rohatgi A. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. Curr Atheroscler Rep 2016;18:2. [PMID: 26710794 DOI: 10.1007/s11883-015-0554-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
589 Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S, Liu S, Kritchevsky S, Wakelee HA, Stefanick ML. Statin use and all-cancer survival: prospective results from the Women's Health Initiative. Br J Cancer 2016;115:129-35. [PMID: 27280630 DOI: 10.1038/bjc.2016.149] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
590 Castilla E, Morillas P, Gómez M, Ahumada M, Monteagudo M, Fácila L, Pallares V. [Use of the CHADS2 score as a predictor of the risk of mortality in hypertensive patients. The FAPRES study]. Med Clin (Barc) 2016;146:478-83. [PMID: 27143530 DOI: 10.1016/j.medcli.2016.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
591 Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Diabetes Res 2016;2016:5147468. [PMID: 27340676 DOI: 10.1155/2016/5147468] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
592 Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J 2016;176:63-9. [PMID: 27264221 DOI: 10.1016/j.ahj.2016.01.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
593 Committee for the Korean Guidelines for the Management of Dyslipidemia. 2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). Korean Circ J 2016;46:275-306. [PMID: 27275165 DOI: 10.4070/kcj.2016.46.3.275] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
594 Fatema K, Rahman B, Zwar NA, Milton AH, Ali L. Short-term predictive ability of selected cardiovascular risk prediction models in a rural Bangladeshi population: a case-cohort study. BMC Cardiovasc Disord 2016;16:105. [PMID: 27386836 DOI: 10.1186/s12872-016-0279-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
595 Gosling OE, Morgan-Hughes G, Bellenger NG. Cardiac imaging to investigate suspected cardiac pain in the post-treadmill era. Clin Med (Lond) 2014;14:475-81. [PMID: 25301906 DOI: 10.7861/clinmedicine.14-5-475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
596 Ishii M, Kaikita K, Sato K, Yamanaga K, Miyazaki T, Akasaka T, Tabata N, Arima Y, Sueta D, Sakamoto K. Impact of statin therapy on clinical outcome in patients with coronary spasm. J Am Heart Assoc. 2016;5:pii: e003426. [PMID: 27207970 DOI: 10.1161/jaha.116.003426] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
597 Coon SA, Ashjian EJ, Herink MC. Current Use of Statins for Primary Prevention of Cardiovascular Disease: Patient-Reported Outcomes and Adherence. Curr Cardiovasc Risk Rep 2016;10. [DOI: 10.1007/s12170-016-0504-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
598 Ma Y, Persuitte GM, Andrews C, Hovey KM, LaMonte MJ, Culver AL, Manson JE, Phillips LS, Liu S, Eaton C, Martin LW, Howard BV, Balasubramanian R, Bird CE, Ockene IS, Sturgeon SR, Ockene JK, Tinker L, Nassir R, Rossouw J. Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin use history among postmenopausal women. Eur J Epidemiol 2016;31:747-61. [PMID: 27188186 DOI: 10.1007/s10654-016-0153-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
599 Schweizer MT, Yu EY. Targeting intratumoral androgens: statins and beyond. Ther Adv Med Oncol 2016;8:388-95. [PMID: 27583031 DOI: 10.1177/1758834016647962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
600 Stevens W, Peneva D, Li JZ, Liu LZ, Liu G, Gao R, Lakdawalla DN. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res. 2016;16:175. [PMID: 27165638 DOI: 10.1186/s12913-016-1420-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
601 Ble A, Hughes PM, Delgado J, Masoli JA, Bowman K, Zirk-Sadowski J, Mujica Mota RE, Henley WE, Melzer D. Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study. J Gerontol A Biol Sci Med Sci 2017;72:243-50. [PMID: 27146371 DOI: 10.1093/gerona/glw082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
602 Pan H, Yang Q, Huang G, Ding C, Cao P, Huang L, Xiao T, Guo J, Su Z. Hypolipidemic effects of chitosan and its derivatives in hyperlipidemic rats induced by a high-fat diet. Food Nutr Res 2016;60:31137. [PMID: 27146338 DOI: 10.3402/fnr.v60.31137] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
603 Pletcher MJ, Vittinghoff E, Thanataveerat A, Bibbins-Domingo K, Moran AE. Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. PLoS One 2016;11:e0154288. [PMID: 27138014 DOI: 10.1371/journal.pone.0154288] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
604 Warren JB, Dimmitt SB, Stampfer HG. Cholesterol trials and mortality. Br J Clin Pharmacol 2016;82:168-77. [PMID: 27043432 DOI: 10.1111/bcp.12945] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
605 Zhang H, Mo XB, Xu T, Lei SF, Zhang YH. Detecting novel genes for low-density lipoprotein cholesterol in European population using bioinformatics analysis. Per Med 2016;13:225-31. [PMID: 29767610 DOI: 10.2217/pme.16.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
606 Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 2016;105:783-90. [PMID: 27120330 DOI: 10.1007/s00392-016-0991-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
607 Mitchell S, Roso S, Samuel M, Pladevall-Vila M. Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord 2016;16:74. [PMID: 27114245 DOI: 10.1186/s12872-016-0241-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
608 Kones R, Rumana U. Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs 2015;75:1187-99. [PMID: 26115727 DOI: 10.1007/s40265-015-0428-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
609 Karmali KN, Lee JY, Brown T, Persell SD. Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers. Prev Med 2016;88:176-81. [PMID: 27090436 DOI: 10.1016/j.ypmed.2016.04.011] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
610 Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag 2016;12:163-9. [PMID: 27143910 DOI: 10.2147/VHRM.S82387] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
611 Li Y, Fuchimoto D, Sudo M, Haruta H, Lin QF, Takayama T, Morita S, Nochi T, Suzuki S, Sembon S, Nakai M, Kojima M, Iwamoto M, Hashimoto M, Yoda S, Kunimoto S, Hiro T, Matsumoto T, Mitsumata M, Sugitani M, Saito S, Hirayama A, Onishi A. Development of Human-Like Advanced Coronary Plaques in Low-Density Lipoprotein Receptor Knockout Pigs and Justification for Statin Treatment Before Formation of Atherosclerotic Plaques. J Am Heart Assoc 2016;5:e002779. [PMID: 27091180 DOI: 10.1161/JAHA.115.002779] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
612 Mayer M. Low-density lipoprotein cholesterol goals: still not in patients' best interest. Evid Based Med 2016;21:128-33. [PMID: 27048840 DOI: 10.1136/ebmed-2016-110383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
613 Barrett B, Ricco J, Wallace M, Kiefer D, Rakel D. Communicating statin evidence to support shared decision-making. BMC Fam Pract 2016;17:41. [PMID: 27048421 DOI: 10.1186/s12875-016-0436-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
614 Unnikrishnan AG, Kalra S, Mithal A. Of statins and low-density lipoprotein cholesterol, "fats" and fiction. Indian J Endocrinol Metab 2016;20:151-3. [PMID: 27042406 DOI: 10.4103/2230-8210.176344] [Reference Citation Analysis]
615 Leusink M, Maitland-van der Zee AH, Ding B, Drenos F, van Iperen EP, Warren HR, Caulfield MJ, Cupples LA, Cushman M, Hingorani AD, Hoogeveen RC, Hovingh GK, Kumari M, Lange LA, Munroe PB, Nyberg F, Schreiner PJ, Sivapalaratnam S, de Bakker PI, de Boer A, Keating BJ, Asselbergs FW, Onland-Moret NC. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics 2016;17:583-91. [PMID: 27045730 DOI: 10.2217/pgs.16.8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
616 Vancheri F, Backlund L, Strender LE, Godman B, Wettermark B. Time trends in statin utilisation and coronary mortality in Western European countries. BMJ Open 2016;6:e010500. [PMID: 27029774 DOI: 10.1136/bmjopen-2015-010500] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
617 Watson KE, Wiesner P. Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit? Circ Cardiovasc Qual Outcomes 2016;9:97-9. [PMID: 26957516 DOI: 10.1161/CIRCOUTCOMES.116.002675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
618 Dang A, Kaur K. Comparative effectiveness research and its utility in In-clinic practice. Perspect Clin Res 2016;7:9-14. [PMID: 26955571 DOI: 10.4103/2229-3485.173780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
619 Lockyer S, Rowland I, Spencer JPE, Yaqoob P, Stonehouse W. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. Eur J Nutr. 2017;56:1421-1432. [PMID: 26951205 DOI: 10.1007/s00394-016-1188-y] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 15.0] [Reference Citation Analysis]
620 Tragante V, Asselbergs FW, Swerdlow DI, Palmer TM, Moore JH, de Bakker PIW, Keating BJ, Holmes MV. Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Hum Genet 2016;135:453-67. [PMID: 26946290 DOI: 10.1007/s00439-016-1647-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
621 Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, Yeo TC, Lim BP. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. Drugs Aging. 2015;32:649-661. [PMID: 26245770 DOI: 10.1007/s40266-015-0290-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
622 Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, Stein CM. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J 2017;17:204-8. [PMID: 26902539 DOI: 10.1038/tpj.2016.3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
623 Dutta NK, Bruiners N, Pinn ML, Zimmerman MD, Prideaux B, Dartois V, Gennaro ML, Karakousis PC. Statin adjunctive therapy shortens the duration of TB treatment in mice. J Antimicrob Chemother 2016;71:1570-7. [PMID: 26903278 DOI: 10.1093/jac/dkw014] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
624 . Two new lipid-regulating drugs. Drug Ther Bull 2016;54:18-21. [PMID: 26868931 DOI: 10.1136/dtb.2016.2.0381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
625 Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation 2016;133:1073-80. [PMID: 26864092 DOI: 10.1161/CIRCULATIONAHA.115.019014] [Cited by in Crossref: 127] [Cited by in F6Publishing: 135] [Article Influence: 21.2] [Reference Citation Analysis]
626 Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ, Caraballo PJ. Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients. J Gen Intern Med. 2016;31:502-508. [PMID: 26850412 DOI: 10.1007/s11606-015-3583-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
627 Zhang ZK, Li J, Yan DX, Leung WN, Zhang BT. Icaritin Inhibits Collagen Degradation-Related Factors and Facilitates Collagen Accumulation in Atherosclerotic Lesions: A Potential Action for Plaque Stabilization. Int J Mol Sci 2016;17:E169. [PMID: 26828485 DOI: 10.3390/ijms17020169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
628 Yamashita S, Masuda D, Ohama T, Arai H, Bujo H, Kagimura T, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y; PROSPECTIVE Study Group. Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. J Atheroscler Thromb 2016;23:746-56. [PMID: 26803913 DOI: 10.5551/jat.32813] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
629 Robson J, Dostal I, Sheikh A, Eldridge S, Madurasinghe V, Griffiths C, Coupland C, Hippisley-Cox J. The NHS Health Check in England: an evaluation of the first 4 years. BMJ Open 2016;6:e008840. [PMID: 26762161 DOI: 10.1136/bmjopen-2015-008840] [Cited by in Crossref: 93] [Cited by in F6Publishing: 97] [Article Influence: 15.5] [Reference Citation Analysis]
630 Chee YJ, Chan HH, Tan NC. Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review. Singapore Med J 2014;55:416-21. [PMID: 25189302 DOI: 10.11622/smedj.2014099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
631 Betteridge DJ, Carmena R. The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol 2016;12:99-110. [PMID: 26668119 DOI: 10.1038/nrendo.2015.194] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
632 Kallend DG, Reijers JA, Bellibas SE, Bobillier A, Kempen H, Burggraaf J, Moerland M, Wijngaard PL. A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur Heart J Cardiovasc Pharmacother 2016;2:23-9. [PMID: 27418968 DOI: 10.1093/ehjcvp/pvv041] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
633 Musicki B, Bella AJ, Bivalacqua TJ, Davies KP, DiSanto ME, Gonzalez-Cadavid NF, Hannan JL, Kim NN, Podlasek CA, Wingard CJ, Burnett AL. Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction. J Sex Med 2015;12:2233-55. [PMID: 26646025 DOI: 10.1111/jsm.13069] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
634 Kim D. The associations between US state and local social spending, income inequality, and individual all-cause and cause-specific mortality: The National Longitudinal Mortality Study. Prev Med 2016;84:62-8. [PMID: 26607868 DOI: 10.1016/j.ypmed.2015.11.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
635 Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R, Cass A, Craig J, Gray A, Collins R, Landray MJ, Baigent C; SHARP Collaborative Group. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2016;67:576-84. [PMID: 26597925 DOI: 10.1053/j.ajkd.2015.09.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
636 Del Gobbo LC, Falk MC, Feldman R, Lewis K, Mozaffarian D. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. Am J Clin Nutr 2015;102:1347-56. [PMID: 26561616 DOI: 10.3945/ajcn.115.110965] [Cited by in Crossref: 155] [Cited by in F6Publishing: 172] [Article Influence: 22.1] [Reference Citation Analysis]
637 Basu S, Bendavid E, Sood N. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis. Circ Cardiovasc Qual Outcomes 2015;8:541-51. [PMID: 26555122 DOI: 10.1161/CIRCOUTCOMES.115.001994] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
638 Gidding SS, Rana JS, Prendergast C, McGill H, Carr JJ, Liu K, Colangelo LA, Loria CM, Lima J, Terry JG, Reis JP, McMahan CA. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Risk Score in Young Adults Predicts Coronary Artery and Abdominal Aorta Calcium in Middle Age: The CARDIA Study. Circulation 2016;133:139-46. [PMID: 27028434 DOI: 10.1161/CIRCULATIONAHA.115.018042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
639 Navar AM, Wang TY, Goldberg AC, Robinson JG, Roger VL, Wilson PF, Virani SS, Elassal J, Lee LV, Webb LE, Peterson E. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2015;170:865-71. [PMID: 26542493 DOI: 10.1016/j.ahj.2015.08.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
640 Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Patients who discontinued statin treatment: a protocol for cohort study using primary care data. BMJ Open 2015;5:e008701. [PMID: 26493458 DOI: 10.1136/bmjopen-2015-008701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
641 Kim BK, Kim HC, Ha KH, Kim DJ. Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients. J Korean Med Sci 2015;30:1612-7. [PMID: 26539005 DOI: 10.3346/jkms.2015.30.11.1612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
642 Han BH, Weinberger Y, Sutin D. Statinopause. J Gen Intern Med 2014;29:1702-6. [PMID: 25092007 DOI: 10.1007/s11606-014-2959-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
643 de la Sierra A, Pintó X, Guijarro C, Miranda JL, Callejo D, Cuervo J, Subirà R, Rubio M. Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain. Adv Ther 2015;32:944-61. [PMID: 26499178 DOI: 10.1007/s12325-015-0252-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
644 Dzien A, Winner H, Theurl E, Dzien-bischinger C, Lechleitner M. Ageing and fasting glucose values – the role of cardiovascular events. European Geriatric Medicine 2015;6:437-41. [DOI: 10.1016/j.eurger.2015.05.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
645 Crossey E, Amar MJA, Sampson M, Peabody J, Schiller JT, Chackerian B, Remaley AT. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 2015;33:5747-55. [PMID: 26413878 DOI: 10.1016/j.vaccine.2015.09.044] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
646 Kritharides L, Nicholls SJ. Men and women--similar but not identical: insights into LDL-lowering therapy in women from the Cholesterol Treatment Trialists Collaboration. Future Cardiol 2015;11:511-5. [PMID: 26406297 DOI: 10.2217/fca.15.46] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
647 Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk. BMJ Open Diabetes Res Care 2015;3:e000132. [PMID: 26435839 DOI: 10.1136/bmjdrc-2015-000132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
648 Hegele RA, Gidding SS, Ginsberg HN, McPherson R, Raal FJ, Rader DJ, Robinson JG, Welty FK. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol 2015;35:2269-80. [PMID: 26376908 DOI: 10.1161/ATVBAHA.115.306442] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
649 Pedro-Botet J, Climent E, Chillarón JJ, Toro R, Benaiges D, Flores-Le Roux JA. Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol 2015;12:431-8. [PMID: 26345308 DOI: 10.11909/j.issn.1671-5411.2015.04.016] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
650 Ohshiro T, Ohtawa M, Nagamitsu T, Matsuda D, Yagyu H, Davis MA, Rudel LL, Ishibashi S, Tomoda H. New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models. J Pharmacol Exp Ther 2015;355:299-307. [PMID: 26338984 DOI: 10.1124/jpet.115.227348] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
651 Bonovas S. Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes? Drugs. 2014;74:1841-1848. [PMID: 25288321 DOI: 10.1007/s40265-014-0309-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
652 Block RC, Abdolahi A, Niemiec CP, Rigby CS, Williams GC. Effects of an evidence-based computerized virtual clinician on low-density lipoprotein and non-high-density lipoprotein cholesterol in adults without cardiovascular disease: The Interactive Cholesterol Advisory Tool. Health Informatics J 2016;22:897-910. [PMID: 26297222 DOI: 10.1177/1460458215600040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
653 Sandercock PA. Does personalized medicine exist and can you test it in a clinical trial? Int J Stroke 2015;10:994-9. [PMID: 26282857 DOI: 10.1111/ijs.12597] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
654 Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clin Cardiol 2015;38:763-9. [PMID: 26282344 DOI: 10.1002/clc.22441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
655 Ahn E, Shin DW, Yang HK, Yun JM, Chun SH, Suh B, Lee H, Son KY, Cho B. Treatment Gap in the National Health-screening Program in Korea: Claim-based Follow-up of Statin Use for Sustained Hypercholesterolemia. J Korean Med Sci 2015;30:1266-72. [PMID: 26339166 DOI: 10.3346/jkms.2015.30.9.1266] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
656 Schoenfeld SR, Lu L, Rai SK, Seeger JD, Zhang Y, Choi HK. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 2016;75:1315-20. [PMID: 26245753 DOI: 10.1136/annrheumdis-2015-207714] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
657 Hung RK, Al-Mallah MH, Qadi MA, Shaya GE, Blumenthal RS, Nasir K, Brawner CA, Keteyian SJ, Blaha MJ. Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford ExercIse Testing Project. Am Heart J 2015;170:390-9. [PMID: 26299238 DOI: 10.1016/j.ahj.2015.04.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
658 Dimmitt SB, Moran A, Scartozzi M, Stampfer HG, Warren JB. Excessive range of statin dose in Western Australian primary care: Excessive range statin dose. Intern Med J 2015;45:860-3. [DOI: 10.1111/imj.12787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
659 DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol 2015; 7(7): 404-409 [PMID: 26225201 DOI: 10.4330/wjc.v7.i7.404] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
660 Kim CA, Kim DH. Statins Provide Less Benefit in Populations with High Noncardiovascular Mortality Risk: Meta-Regression of Randomized Controlled Trials. J Am Geriatr Soc 2015;63:1413-9. [PMID: 26173475 DOI: 10.1111/jgs.13476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
661 Sekikawa A, Miyamoto Y, Miura K, Nishimura K, Willcox BJ, Masaki KH, Rodriguez B, Tracy RP, Okamura T, Kuller LH. Continuous decline in mortality from coronary heart disease in Japan despite a continuous and marked rise in total cholesterol: Japanese experience after the Seven Countries Study. Int J Epidemiol 2015;44:1614-24. [PMID: 26182938 DOI: 10.1093/ije/dyv143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
662 Hu Z, Zaman MJ, Wang J, Peacock JL, Chen R. Correlates of Untreated Hypercholesterolemia in Older Adults: A Community-Based Household Survey in China. PLoS One 2015;10:e0131318. [PMID: 26161751 DOI: 10.1371/journal.pone.0131318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
663 Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis. 2015;242:29-36. [PMID: 26164157 DOI: 10.1016/j.atherosclerosis.2015.06.042] [Cited by in Crossref: 75] [Cited by in F6Publishing: 86] [Article Influence: 10.7] [Reference Citation Analysis]
664 Odden MC, Pletcher MJ, Coxson PG, Thekkethala D, Guzman D, Heller D, Goldman L, Bibbins-Domingo K. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med 2015;162:533-41. [PMID: 25894023 DOI: 10.7326/M14-1430] [Cited by in Crossref: 70] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
665 Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, Xie J, Kang LN, Xu B. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. [PMID: 26099511 DOI: 10.1186/s12916-015-0358-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 141] [Article Influence: 19.9] [Reference Citation Analysis]
666 Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol 2015;12:508-30. [PMID: 26076950 DOI: 10.1038/nrcardio.2015.82] [Cited by in Crossref: 136] [Cited by in F6Publishing: 159] [Article Influence: 19.4] [Reference Citation Analysis]
667 Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, Luo H, Cai Y, Zeng C. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015;4:e001937. [PMID: 26077586 DOI: 10.1161/JAHA.115.001937] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
668 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 91] [Article Influence: 14.3] [Reference Citation Analysis]
669 Brinkmann SJ, Wörner EA, Buijs N, Richir M, Cynober L, van Leeuwen PA, Couderc R. The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine. Int J Mol Sci 2015;16:12230-42. [PMID: 26035753 DOI: 10.3390/ijms160612230] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
670 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015;161:161-72. [PMID: 25815993 DOI: 10.1016/j.cell.2015.01.036] [Cited by in Crossref: 480] [Cited by in F6Publishing: 423] [Article Influence: 68.6] [Reference Citation Analysis]
671 Kim DS, Burt AA, Ranchalis JE, Vuletic S, Vaisar T, Li WF, Rosenthal EA, Dong W, Eintracht JF, Motulsky AG, Brunzell JD, Albers JJ, Furlong CE, Jarvik GP. PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. J Lipid Res 2015;56:1351-62. [PMID: 26009633 DOI: 10.1194/jlr.P058032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
672 Alpérovitch A, Kurth T, Bertrand M, Ancelin ML, Helmer C, Debette S, Tzourio C. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ 2015;350:h2335. [PMID: 25989805 DOI: 10.1136/bmj.h2335] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
673 Zhao J, Zhang X, Dong L, Wen Y, Cui L. The many roles of statins in ischemic stroke. Curr Neuropharmacol 2014;12:564-74. [PMID: 25977681 DOI: 10.2174/1570159X12666140923210929] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
674 Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M. Lipid-modifying therapy in the elderly. Vasc Health Risk Manag 2015;11:251-63. [PMID: 25999729 DOI: 10.2147/VHRM.S40474] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
675 deGoma EM, Salavati A, Shinohara RT, Saboury B, Pollan L, Schoen M, Torigian DA, Mohler ER, Dunbar RL, Litt HI, Woo J, Rader DJ, Alavi A, Mehta NN. A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. Acad Radiol 2015;22:600-9. [PMID: 25708866 DOI: 10.1016/j.acra.2014.12.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
676 Enas EA, Dharmarajan TS, Varkey B. Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. Indian Heart J 2015;67:95-102. [PMID: 26071285 DOI: 10.1016/j.ihj.2015.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
677 Vincze J, Jenes Á, Füzi M, Almássy J, Németh R, Szigeti G, Dienes B, Gaál Z, Szentesi P, Jóna I, Kertai P, Paragh G, Csernoch L. Effects of fluvastatin and coenzyme Q10 on skeletal muscle in normo- and hypercholesterolaemic rats. J Muscle Res Cell Motil 2015;36:263-74. [PMID: 25920381 DOI: 10.1007/s10974-015-9413-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
678 Andersson C, Enserro D, Larson MG, Xanthakis V, Vasan RS. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc 2015;4:e001888. [PMID: 25888372 DOI: 10.1161/JAHA.115.001888] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
679 Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm 2015;2015:718329. [PMID: 25960621 DOI: 10.1155/2015/718329] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 12.9] [Reference Citation Analysis]
680 Packard CJ, Weintraub WS, Laufs U. New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vascul Pharmacol 2015;71:37-9. [PMID: 25889746 DOI: 10.1016/j.vph.2015.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
681 Armah CN, Derdemezis C, Traka MH, Dainty JR, Doleman JF, Saha S, Leung W, Potter JF, Lovegrove JA, Mithen RF. Diet rich in high glucoraphanin broccoli reduces plasma LDL cholesterol: Evidence from randomised controlled trials. Mol Nutr Food Res 2015;59:918-26. [PMID: 25851421 DOI: 10.1002/mnfr.201400863] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
682 Smiderle L, Lima LO, Hutz MH, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Almeida S, Fiegenbaum M. Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort. Arq Bras Cardiol 2014;103:33-40. [PMID: 25120083 DOI: 10.5935/abc.20140085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
683 Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Clin Ther 2015;37:804-15. [PMID: 25626487 DOI: 10.1016/j.clinthera.2014.12.019] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
684 van der Sluis RJ, Nahon JE, Reuwer AQ, Van Eck M, Hoekstra M. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice.Br J Pharmacol. 2015;172:2397-2405. [PMID: 25572138 DOI: 10.1111/bph.13067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
685 Chogtu B, Magazine R, Bairy K. Statin use and risk of diabetes mellitus. World J Diabetes 2015; 6(2): 352-357 [PMID: 25789118 DOI: 10.4239/wjd.v6.i2.352] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
686 Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol 2015;179:173-87. [PMID: 25352024 DOI: 10.1111/cei.12477] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 11.4] [Reference Citation Analysis]
687 Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol. 2015;12:301-311. [PMID: 25754885 DOI: 10.1038/nrcardio.2015.28] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
688 Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015;385:2264-71. [PMID: 25748612 DOI: 10.1016/S0140-6736(14)61730-X] [Cited by in Crossref: 356] [Cited by in F6Publishing: 143] [Article Influence: 50.9] [Reference Citation Analysis]
689 Salmoirago-Blotcher E, Hovey KM, Andrews CA, Robinson JG, Johnson KC, Wassertheil-Smoller S, Crawford S, Qi L, Martin LW, Ockene J, Manson JE. Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. BMJ Open 2015;5:e007075. [PMID: 25716175 DOI: 10.1136/bmjopen-2014-007075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
690 Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med 2014;174:1964-71. [PMID: 25285455 DOI: 10.1001/jamainternmed.2014.5336] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 16.4] [Reference Citation Analysis]
691 Halcox JP, Tubach F, Lopez-Garcia E, De Backer G, Borghi C, Dallongeville J, Guallar E, Medina J, Perk J, Sazova O, Sweet S, Roy C, Banegas JR, Rodriguez-Artalejo F. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS One 2015;10:e0115270. [PMID: 25692692 DOI: 10.1371/journal.pone.0115270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
692 Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015;36:1186-94. [PMID: 25687353 DOI: 10.1093/eurheartj/ehv028] [Cited by in Crossref: 250] [Cited by in F6Publishing: 244] [Article Influence: 35.7] [Reference Citation Analysis]
693 Annigeri RA, Mani RM. Acute interstitial nephritis due to statin and its class effect. Indian J Nephrol 2015;25:54-6. [PMID: 25684874 DOI: 10.4103/0971-4065.136883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
694 Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215-23. [PMID: 24821892 DOI: 10.1370/afm.1641] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
695 Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, Oh J, Zimmerman CO, Hwang J, Abbara S, Plutzky J, Robbins G, Tawakol A, Hoffmann U, Grinspoon SK. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015;2:e52-63. [PMID: 26424461 DOI: 10.1016/S2352-3018(14)00032-0] [Cited by in Crossref: 139] [Cited by in F6Publishing: 145] [Article Influence: 19.9] [Reference Citation Analysis]
696 De Caterina R. The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. Intern Emerg Med 2015;10:115-7. [PMID: 25502589 DOI: 10.1007/s11739-014-1159-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
697 van Hasselt FM, Krabbe PF, Postma MJ, Loonen AJ. Evaluation of health promotion programmes in severe mental illness: theory and practice. Int J Methods Psychiatr Res 2015;24:83-97. [PMID: 25488507 DOI: 10.1002/mpr.1456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
698 Schulman-Marcus J, Hartaigh BÓ, Giambrone AE, Gransar H, Valenti V, Berman DS, Budoff MJ, Achenbach S, Al-Mallah M, Andreini D, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJ, Cury R, Delago A, Hadamitzky M, Hausleiter J, Feuchtner G, Kim YJ, Kaufmann PA, Leipsic J, Lin FY, Maffei E, Pontone G, Raff G, Shaw LJ, Villines TC, Dunning A, Min JK. Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: results from the multicenter CONFIRM registry. Atherosclerosis 2015;238:119-25. [PMID: 25479800 DOI: 10.1016/j.atherosclerosis.2014.11.007] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
699 Gryn SE, Hegele RA. Doctor my eyes: a statin-cataract connection? Can J Cardiol 2014;30:1508-10. [PMID: 25475455 DOI: 10.1016/j.cjca.2014.08.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
700 Ibrahim C, Ban MR, Hegele RA. The effect of infrequent low-dose rosuvastatin on the lipid profile. Can J Cardiol 2014;30:1392-5. [PMID: 25442436 DOI: 10.1016/j.cjca.2014.07.002] [Reference Citation Analysis]
701 Dubé JB, Wang J, Cao H, McIntyre AD, Johansen CT, Hopkins SE, Stringer R, Hosseinzadeh S, Kennedy BA, Ban MR, Young TK, Connelly PW, Dewailly E, Bjerregaard P, Boyer BB, Hegele RA. Common low-density lipoprotein receptor p.G116S variant has a large effect on plasma low-density lipoprotein cholesterol in circumpolar inuit populations. Circ Cardiovasc Genet 2015;8:100-5. [PMID: 25414273 DOI: 10.1161/CIRCGENETICS.114.000646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
702 McFadden E, Stevens R, Glasziou P, Perera R. Implications of lower risk thresholds for statin treatment in primary prevention: analysis of CPRD and simulation modelling of annual cholesterol monitoring. Prev Med 2015;70:14-6. [PMID: 25445333 DOI: 10.1016/j.ypmed.2014.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
703 McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV, Davey AK. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15:20607-20637. [PMID: 25391045 DOI: 10.3390/ijms151120607] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 12.6] [